uht-10q_20160930.htm

0001564590-16-028351.txt : 20161108 0001564590-16-028351.hdr.sgml : 20161108 20161108162407 ACCESSION NUMBER: 0001564590-16-028351 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161108 DATE AS OF CHANGE: 20161108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNIVERSAL HEALTH REALTY INCOME TRUST CENTRAL INDEX KEY: 0000798783 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 236858580 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09321 FILM NUMBER: 161981569 BUSINESS ADDRESS: STREET 1: UNIVERSAL CORPORATE CTR STREET 2: 367 S GULPH RD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 BUSINESS PHONE: 610-265-0688 MAIL ADDRESS: STREET 1: UNIVERSAL CORPORATE CTR STREET 2: 367 S GULPH ROAD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 10-Q 1 uht-10q_20160930.htm 10-Q uht-10q_20160930.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(MARK ONE)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 1-9321

UNIVERSAL HEALTH REALTY INCOME TRUST

(Exact name of registrant as specified in its charter)

MARYLAND		23-6858580
(State or other jurisdiction of incorporation or organization)		(I. R. S. Employer Identification No.)

UNIVERSAL CORPORATE CENTER 367 SOUTH GULPH ROAD KING OF PRUSSIA, PENNSYLVANIA		19406
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (610) 265-0688

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated Filer	☒

Non-accelerated filer	☐	Smaller reporting company	☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Number of common shares of beneficial interest outstanding at October 31, 2016—13,598,144

UNIVERSAL HEALTH REALTY INCOME TRUST

INDEX

		PAGE NO.
PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements
	Condensed Consolidated Statements of Income—Three and Nine Months Ended September 30, 2016 and 2015	3
	Condensed Consolidated Statements of Comprehensive Income—Three and Nine Months Ended September 30, 2016 and 2015	4
	Condensed Consolidated Balance Sheets—September 30, 2016 and December 31, 2015	5
	Condensed Consolidated Statements of Cash Flows—Nine Months Ended September 30, 2016 and 2015	6
	Notes to Condensed Consolidated Financial Statements	7 through 16
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17 through 26
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27
Item 4.	Controls and Procedures	27
PART II. Other Information		28
Item 6.	Exhibits	28
Signatures		29
EXHIBIT INDEX		30

This Quarterly Report on Form 10-Q is for the quarter ended September 30, 2016. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

As disclosed in this Quarterly Report, including in Part I, Item 1.—Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions, a wholly-owned subsidiary of UHS (UHS of Delaware, Inc.) serves as our Advisor pursuant to the terms of an annually renewable Advisory Agreement dated December 24, 1986. Our officers are all employees of UHS through its wholly-owned subsidiary, UHS of Delaware, Inc. In addition, three of our hospital facilities are leased to subsidiaries of UHS and seventeen medical office buildings, including one under construction, or free-standing emergency departments, that are either wholly or jointly-owned by us, include or will include tenants which are subsidiaries of UHS. Any reference to “UHS” or “UHS facilities” in this report is referring to Universal Health Services, Inc.’s subsidiaries, including UHS of Delaware, Inc.

In this Quarterly Report, the term “revenues” does not include the revenues of the unconsolidated limited liability companies (“LLCs”) in which we have various non-controlling equity interests ranging from 33% to 95%. We currently account for our share of the income/loss from these investments by the equity method (see Note 5 to the Condensed Consolidated Financial Statements included herein).

Part I. Financial Information

Item I. Financial Statements

Universal Health Realty Income Trust

Condensed Consolidated Statements of Income

For the Three and Nine Months Ended September 30, 2016 and 2015

(amounts in thousands, except per share amounts)

(unaudited)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2016			2015			2016			2015
Revenues:
Base rental - UHS facilities	$	4,066		$	4,019		$	12,226		$	11,916
Base rental - Non-related parties		9,273			8,763			27,118			26,438
Bonus rental - UHS facilities		1,118			1,085			3,557			3,453
Tenant reimbursements and other - Non-related parties		2,168			1,620			5,984			5,523
Tenant reimbursements and other - UHS facilities		176			199			603			607
		16,801			15,686			49,488			47,937
Expenses:
Depreciation and amortization		5,893			5,424			16,872			16,817
Advisory fees to UHS		832			708			2,380			2,067
Other operating expenses		4,663			4,461			13,603			13,921
Transaction costs		331			-			477			204
		11,719			10,593			33,332			33,009
Income before equity in income of unconsolidated limited liability companies ("LLCs"), interest expense and gain		5,082			5,093			16,156			14,928
Equity in income of unconsolidated LLCs		1,110			561			3,396			1,826
Gain on property exchange		-			-			-			8,742
Interest expense, net		(2,374	)		(2,015	)		(6,783	)		(6,157	)
Net income	$	3,818		$	3,639		$	12,769		$	19,339
Basic earnings per share	$	0.28		$	0.27		$	0.95		$	1.46
Diluted earnings per share	$	0.28		$	0.27		$	0.95		$	1.45

Weighted average number of shares outstanding - Basic		13,575			13,298			13,426			13,289
Weighted average number of share equivalents		-			4			5			8
Weighted average number of shares and equivalents outstanding - Diluted		13,575			13,302			13,431			13,297

See accompanying notes to these condensed consolidated financial statements.

Universal Health Realty Income Trust

Condensed Consolidated Statements of Comprehensive Income

For the Three and Nine Months Ended September 30, 2016 and 2015

(dollar amounts in thousands)

(unaudited)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2016			2015			2016			2015
Net income	$	3,818		$	3,639		$	12,769		$	19,339
Other comprehensive income/(loss):
Unrealized losses on interest rate caps		(7	)		(15	)		(75	)		(94	)
Amortization of interest rate cap fees		23			23			69			69
Total other comprehensive income/(loss):		16			8			(6	)		(25	)
Total comprehensive income	$	3,834		$	3,647		$	12,763		$	19,314

See accompanying notes to these condensed consolidated financial statements.

Universal Health Realty Income Trust

Condensed Consolidated Balance Sheets

(dollar amounts in thousands)

(unaudited)

	September 30,			December 31,
	2016			2015
Assets:
Real Estate Investments:
Buildings and improvements and construction in progress	$	517,726		$	469,933
Accumulated depreciation		(133,929	)		(121,161	)
		383,797			348,772
Land		48,615			41,724
Net Real Estate Investments		432,412			390,496
Investments in and advances to limited liability companies ("LLCs")		36,765			31,597
Other Assets:
Cash and cash equivalents		3,982			3,894
Base and bonus rent receivable from UHS		2,256			2,116
Rent receivable - other		4,649			4,292
Intangible assets (net of accumulated amortization of $25.8 million and $25.1 million at September 30, 2016 and December 31, 2015, respectively)		23,014			19,757
Deferred charges and other assets, net		7,311			6,351
Total Assets	$	510,389		$	458,503
Liabilities:
Line of credit borrowings	$	192,250		$	142,150
Mortgage notes payable, non-recourse to us, net		107,660			110,156
Accrued interest		551			504
Accrued expenses and other liabilities		10,037			6,807
Tenant reserves, deposits and prepaid rents		4,548			3,844
Total Liabilities		315,046			263,461
Equity:
Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized; none issued and outstanding		—			—
Common shares, $.01 par value; 95,000,000 shares authorized; issued and outstanding: 2016 - 13,598,082; 2015 - 13,327,020		136			133
Capital in excess of par value		255,466			241,700
Cumulative net income		568,055			555,286
Cumulative dividends		(628,214	)		(601,983	)
Accumulated other comprehensive loss		(100	)		(94	)
Total Equity		195,343			195,042
Total Liabilities and Equity	$	510,389		$	458,503

See accompanying notes to these condensed consolidated financial statements.

Universal Health Realty Income Trust

Condensed Consolidated Statement of Cash Flows

(dollar amounts in thousands)

(unaudited)

	Nine months ended September 30,
	2016			2015
Cash flows from operating activities:
Net income	$	12,769		$	19,339
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		16,920			16,884
Amortization of debt premium		(166	)		(169	)
Stock-based compensation expense		354			316
Gain on property exchange		—			(8,742	)
Changes in assets and liabilities:
Rent receivable		(497	)		(311	)
Accrued expenses and other liabilities		203			(278	)
Tenant reserves, deposits and prepaid rents		604			869
Accrued interest		47			(75	)
Other, net		(482	)		(533	)
Net cash provided by operating activities		29,752			27,300
Cash flows from investing activities:
Investments in LLCs		(5,454	)		(418	)
Repayments of advances made to LLC		634			—
Cash distributions in excess of income from LLCs		318			168
Cash distribution of refinancing proceeds from LLCs		—			1,045
Additions to real estate investments, net		(7,104	)		(3,667	)
Cash received for property exchange		—			2,000
Deposit on real estate assets		(420	)		—
Net cash paid for acquisition of properties		(52,193	)		(16,765	)
Cash paid to acquire minority interests in majority-owned LLCs		—			(2,250	)
Net cash used in investing activities		(64,219	)		(19,887	)
Cash flows from financing activities:
Net borrowings on line of credit		50,100			24,600
Repayments of mortgages and other notes payable		(2,407	)		(7,383	)
Financing costs paid		(307	)		(1,000	)
Dividends paid		(26,231	)		(25,494	)
Partial settlement of dividend equivalent rights		(30	)		(17	)
Issuance of shares of beneficial interest, net		13,430			1,671
Net cash provided by (used in) financing activities		34,555			(7,623	)
Increase/(decrease) in cash and cash equivalents		88			(210	)
Cash and cash equivalents, beginning of period		3,894			3,861
Cash and cash equivalents, end of period	$	3,982		$	3,651
Supplemental disclosures of cash flow information:
Interest paid	$	6,491		$	6,052
Property Exchange Transaction:
Net assets acquired in property exchange	$	—		$	9,886
Net assets relinquished in property exchange		—			(3,144	)

See accompanying notes to these condensed consolidated financial statements.

UNIVERSAL HEALTH REALTY INCOME TRUST

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2016

(unaudited)

(1) General

In this Quarterly Report on Form 10-Q, the term “revenues” does not include the revenues of the unconsolidated limited liability companies (“LLCs”) in which we have various non-controlling equity interests ranging from 33% to 95%. As of September 30, 2016, we had investments in five jointly-owned LLCs/LPs which own medical office buildings, all of which are accounted for by the equity method (see Note 5). These LLCs are included in our financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.

The financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these financial statements be read in conjunction with the financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2015.

(2) Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions

Leases: We commenced operations in 1986 by purchasing properties of certain subsidiaries from UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and rental terms for each facility are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. These hospital leases with subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.

The combined revenues generated from the leases on the UHS hospital facilities accounted for approximately 23% and 25% of our consolidated revenues for the three months ended September 30, 2016 and 2015, respectively, and approximately 24% and 25% of our consolidated revenues for the nine months ended September 30, 2016 and 2015, respectively. Including 100% of the revenues generated at the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%, the leases on the UHS hospital facilities accounted for approximately 19% and 20% of the combined consolidated and unconsolidated revenue for the three months ended September 30, 2016 and 2015, respectively, and approximately 20% of the combined consolidated and unconsolidated revenue for each of the nine months ended September 30, 2016 and 2015. In addition, we have seventeen medical office buildings (“MOBs”), including one currently under construction, or free-standing emergency departments (“FEDs”), that are either wholly or jointly-owned by us, and include or will include tenants which are subsidiaries of UHS.

Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of all hospital properties with subsidiaries of UHS, UHS has the option to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities at the end of the lease terms or any renewal terms at the appraised fair market value. In addition, the Master Lease, as amended during 2006, includes a change of control provision whereby UHS has the right, upon one month’s notice should a change of control of the Trust occur, to purchase any or all of the three leased hospital properties listed below at their appraised fair market value. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer. The leases related to the hospital facilities of UHS are guaranteed by UHS and cross-defaulted with one another.

existing lease rates, to December, 2021. The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:

Hospital Name	Annual Minimum Rent		End of Lease Term	Renewal Term (years)
McAllen Medical Center	$	5,485,000	December, 2021		10	(a)
Wellington Regional Medical Center	$	3,030,000	December, 2021		10	(b)
Southwest Healthcare System, Inland Valley Campus	$	2,648,000	December, 2021		10	(b)

(a)	UHS has two 5-year renewal options at existing lease rates (through 2031).

(b)	UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).

Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital and FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to the these leases.

During the first quarter of 2016, we committed to invest up to $21.1 million in the development and construction of the Henderson Medical Plaza, an MOB located on the campus of the Henderson Hospital Medical Center which is owned by a UHS subsidiary and opened in late October, 2016. A ground lease has been executed between the limited liability company that owns the MOB and a subsidiary of UHS, the terms of which include a seventy-five year lease term with two ten-year renewal options at the Lessee’s option at an adjusting lease rate. We have invested $4.6 million in this MOB as of September 30, 2016. The MOB is scheduled to be completed and opened during the first quarter of 2017.

Advisory Agreement: UHS of Delaware, Inc. (the “Advisor”), a wholly-owned subsidiary of UHS, serves as Advisor to us under an Advisory Agreement (the “Advisory Agreement”) dated December 24, 1986. Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory. In December of 2015, based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the Advisory agreement was renewed for 2016 pursuant to the same terms as the Advisory Agreement in place during 2015.

The average real estate assets for advisory fee calculation purposes exclude certain items from our consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, base and bonus rent receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. In addition, the Advisor is entitled to an annual incentive fee equal to 20% of the amount by which cash available for distribution to shareholders for each year, as defined in the Advisory Agreement, exceeds 15% of our equity as shown on our consolidated balance sheet, determined in accordance with generally accepted accounting principles without reduction for return of capital dividends. The Advisory Agreement defines cash available for distribution to shareholders as net cash flow from operations less deductions for, among other things, amounts required to discharge our debt and liabilities and reserves for replacement and capital improvements to our properties and investments. No incentive fees were paid during the first nine months of 2016 or 2015 since the incentive fee requirements were not achieved. Advisory fees incurred and paid (or payable) to UHS amounted to $832,000 and $708,000 for the three months ended September 30, 2016 and 2015, respectively, and were based upon average invested real estate assets of $475 million and $405 million for the three-month periods ended September 30, 2016 and 2015, respectively. Advisory fees incurred and paid (or payable) to UHS amounted to $2.4 million and $2.1 million for the nine months ended September 30, 2016 and 2015, respectively, and were based upon average invested real estate assets of $453 million and $394 million for the nine-month periods ended September 30, 2016 and 2015, respectively.

stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.

Share Ownership: As of September 30, 2016 and December 31, 2015, UHS owned 5.8% and 5.9%, respectively, of our outstanding shares of beneficial interest.

SEC reporting requirements of UHS: UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the leases on the hospital facilities leased to wholly-owned subsidiaries of UHS comprised approximately 23% and 25% of our consolidated revenues during the three month periods ended September 30, 2016 and 2015, respectively, and comprised approximately 24% and 25% of our consolidated revenues during the nine months ended September 30, 2016 and 2015, respectively, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC’s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.

(3) Dividends and Equity Issuance Program

Dividends:

We declared and paid dividends of $8.8 million, or $.65 per share, during the third quarter of 2016 and $8.5 million, or $.64 per share, during the third quarter of 2015. We declared and paid dividends of $26.2 million, or $1.945 per share, during the nine-month period ended September 30, 2016 and $25.5 million, or $1.915 per share, during the nine-month period ended September 30, 2015.

Equity Issuance Program:

During the second quarter of 2016, we recommenced our at-the-market (“ATM”) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of approximately $23.3 million to or through Merrill Lynch, Pierce, Fenner and Smith, Incorporated (“Merrill Lynch”), as sales agent and/or principal. The common shares were offered pursuant to the Registration Statement filed with the Securities and Exchange Commission, which became effective during the fourth quarter of 2015.

Pursuant to the ATM Program, during the first nine months of 2016, there were 249,016 shares issued at an average price of $55.30 per share (all of which were issued during the second quarter), which generated approximately $13.2 million of cash net proceeds (net of approximately $558,000, consisting of compensation of $344,000 to Merrill Lynch, as well as $214,000 of other various fees and expenses). Since inception of this ATM program, we have issued 829,916 shares at an average price of $48.77 per share, which generated approximately $38.8 million of net proceeds (net of approximately $1.7 million, consisting of compensation of $1.0 million to Merrill Lynch as well as $680,000 of other various fees and expenses).

(4) Acquisitions, Dispositions and New Construction

Nine Months Ended September 30, 2016:

Acquisition:

During the nine months ended September 30, 2016, we spent $52.2 million to:

•

purchase the Frederick Memorial Hospital Crestwood, an MOB located in Frederick, Maryland, during the third quarter for approximately $24.3 million. The property, which consists of approximately 62,300 rentable square feet, is fully occupied pursuant to the terms of triple-net leases with an average remaining lease term of approximately twelve years at the time of acquisition.

•

purchase the Chandler Corporate Center III located in Chandler, Arizona, during the second quarter for approximately $18.0 million. The property, which consists of 82,000 rentable square feet, is currently 92% occupied by one tenant pursuant to the terms of a twelve year escalating triple-net lease, with a ten year fair-market value renewal option. The lease had a remaining lease term of approximately 11.3 years at the time of acquisition.

•

purchase the Madison Professional Office Building located in Madison, Alabama, during the first quarter for approximately $10.1 million (including $150,000 deposit made in 2015). This multi-tenant property consists of approximately 30,100 rentable square feet and is fully occupied with an average remaining lease term of approximately 6.2 years at the time of acquisition.

The aggregate purchase price for these acquisitions was allocated to the assets acquired and liabilities assumed consisting of tangible property and intangible assets and liabilities, based on the fair value estimated or finalized at acquisition as detailed in the table below. Final allocations of the total purchase price for allocations currently estimated will be recorded during the fourth quarter of 2016, pursuant to a third-party appraisal and will be based upon the fair value at acquisition. While they are not expected to be materially different than those shown, any material adjustments to the estimates will be reflected, retroactively, as of the date of acquisition. Previous reported estimated purchase price allocations that have been finalized in the third quarter did not have a material impact on our consolidated financial statements The intangible assets include the value of in-place leases at the properties at the time of acquisition as well as the above market lease values. The value of the in-place leases will be amortized over the average remaining lease terms of approximately 6 to 12 years at the time of acquisition. The above/below market leases, which are reflected below as intangible assets/below-market intangibles will be amortized over the remaining term of the respective leases. The estimated aggregate allocation is as follows:


Land	$6,891
Buildings and improvements	39,647
Intangible assets	7,094
Below-market intangibles	(1,289)
Deposit………………………………………………………………………………………..	(150)

Net cash paid	$52,193

For these properties acquired during 2016, we recorded aggregate net revenue of approximately $723,000 and $1.1 million during the three and nine month periods ended September 30, 2016, respectively, since the date of acquisition. The aggregate net losses generated by these properties since the date of acquisition, including the cost of borrowings and advisory fee expenses was approximately $47,000 and $134,000 during the three and nine month periods ended September 30, 2016, respectively.

Assuming the 2016 acquisitions occurred on January 1, 2015, our pro forma net revenues for the three and nine months ended September 30, 2015, would have been approximately $16.4 million and $50.1 million, respectively, and our pro forma net income for the three and nine months ended September 30, 2015, would have been approximately $3.4 million, or $.25 per diluted share, and $18.7 million, or $1.40 per diluted share, respectively. The Chandler Corporate Center III was not operational during the first nine months of 2015. Assuming these acquisitions occurred on January 1, 2016, our pro forma net revenues for the three and nine months ended September 30, 2016, would have been approximately $17.2 million and $51.7 million, respectively, and the aggregate effect on our net income for the three and nine months ended September 30, 2016 was not material.

New Construction:

at an adjusting lease rate. We have invested $4.6 million on the development and construction for this MOB as of September 30, 2016. The MOB is scheduled to be completed and opened during the first quarter of 2017.

Dispositions:

There were no divestitures during the first nine months of 2016.

Nine Months Ended September 30, 2015:

Property Exchange Transaction:

In May, 2015, in exchange for the real property of Sheffield Medical Building (“Sheffield”), a 73,446 square foot medical office building (“MOB”) located in Atlanta, Georgia, we received $2 million in cash and the real property of two MOBs located in Sandy Springs and Vinings, Georgia, from an unrelated third party. In connection with the two MOBs acquired in this transaction, triple net, master lease agreements applicable to 100% of the combined 36,700 rentable square feet of these properties were executed with the counterparty. These master lease agreements have initial terms of 15 years and provide for 3% annual rent increases. We recorded an $8.7 million gain which is included in our Condensed Consolidated Statements of Income for the nine-month period ended September 30, 2015, representing the difference between recorded net book value of Sheffield and the fair values of the properties exchanged, combined with the cash proceeds received.

Acquisitions:

In February, 2015, we purchased the Haas Medical Office Park, two single story buildings having an aggregate of approximately 16,000 rentable square feet, located in Ottumwa, Iowa, for approximately $4.1 million.

In January and February of 2015, we purchased from wholly-owned subsidiaries of UHS, the real property of two newly-constructed and recently opened FEDs located in Weslaco and Mission, Texas, for an aggregate acquisition cost of approximately $12.8 million. Each FED consists of approximately 13,600 square feet and is operated by wholly-owned subsidiaries of UHS. In connection with these acquisitions, ten-year lease agreements with six 5-year renewal terms were executed with UHS for each FED. In connection with the lease agreements, the lessee shall have the option to purchase the leased property upon the expiration of the fixed term and each five-year extended term at the fair market value at that time.

Dispositions:

There were no divestitures during the first nine months of 2015.

(5) Summarized Financial Information of Equity Affiliates

In accordance with the Financial Accounting Standards Board’s (“FASB”) standards and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting. The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.

At September 30, 2016, we have non-controlling equity investments or commitments in five jointly-owned LLCs/LPs which own MOBs. As of September 30, 2016, we accounted for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities and we do not have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that manage and hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash fundings are typically advanced as equity or member loans. These entities maintain property insurance on the properties.

Effective February 1, 2016, we purchased an additional 10% ownership interest in the Arlington Medical Properties, LLC from the third-party minority member, subject to certain agreed upon terms and conditions. Including this additional ownership interest, we currently own 85% of this LLC which is accounted for on an unconsolidated basis pursuant to the equity method.

The following property table represents the five LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of September 30, 2016:


Name of LLC/LP	Ownership			Property Owned by LLC
Suburban Properties		33	%	St. Matthews Medical Plaza II
Brunswick Associates (a.)		74	%	Mid Coast Hospital MOB
Arlington Medical Properties (b.)		85	%	Saint Mary’s Professional Office Building
Grayson Properties (c.)		95	%	Texoma Medical Plaza
FTX MOB Phase II (d.)		95	%	Forney Medical Plaza II

(a.)	This LLC has a third-party term loan, which is non-recourse to us, of $8.7 million outstanding as of September 30, 2016.

(b.)

We have funded $5.2 million in equity as of September 30, 2016 and are committed to invest an additional $623,000. During the fourth quarter of 2015, we advanced this LLC a member loan, the funds of which were utilized to repay its $22.8 million outstanding third-party mortgage loan on its scheduled maturity date. The terms of the member loan are similar to those in place pursuant to the third-party mortgage loan that was repaid. Additionally, pursuant to the terms and conditions of an agreement executed in February, 2016, we purchased an additional 10% of the ownership interest in this LLC from the existing third-party member for approximately $4.8 million in cash, thereby increasing our ownership interest to 85%.

(c.)

We have funded $2.8 million in equity as of September 30, 2016, and are committed to fund an additional $100,000. This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LLC has a third-party term loan, which is non-recourse to us, of $14.5 million outstanding as of September 30, 2016.

(d.)	We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of September 30, 2016. This LLC has a third-party term loan, which is non-recourse to us, of $5.3 million outstanding as of September 30, 2016.

Below are the condensed combined statements of income (unaudited) for the LLCs accounted for under the equity method at September 30, 2016 and 2015.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
	(amounts in thousands)				(amounts in thousands)
Revenues	$	3,776	$	3,638	$	11,437	$	10,799
Operating expenses		1,329		1,461		4,025		4,194
Depreciation and amortization		646		634		1,910		1,788
Interest, net		636		656		1,928		1,907
Net income	$	1,165	$	887	$	3,574	$	2,910
Our share of net income (a.)	$	1,110	$	561	$	3,396	$	1,826

(a.)

Our share of net income for the three and nine months ended September 30, 2016 includes approximately $291,000 and $880,000, respectively, of interest income earned by us on an advance made to Arlington Medical Properties, LLC (advance balance payable to us is approximately $21.8 million as of September 30, 2016). There were no advances outstanding during the first nine months of 2015, therefore there was no interest income earned by us for the three and nine months ended September 30, 2015. Also, as mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% previously.

Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs in which we hold noncontrolling ownership interests and that were accounted for under the equity method as of September 30, 2016 and December 31, 2015:

	September 30, 2016			December 31, 2015
	(amounts in thousands)
Net property, including CIP	$	61,317		$	61,668
Other assets		5,343			5,264
Total assets	$	66,660		$	66,932

Liabilities	$	2,832		$	2,538
Mortgage notes payable, non-recourse to us		28,497			28,895
Advances payable to us		21,855			22,489
Equity		13,476			13,010
Total liabilities and equity	$	66,660		$	66,932

Our share of equity in and advances to LLCs reflected as:
Investments in LLCs	$	14,910		$	9,108
Advances to LLCs		21,855			22,489
Investments in and advances to LLCs before
amounts included in accrued expenses and other liabilities		36,765			31,597
Amounts included in accrued expenses and other liabilities		(1,771	)		(1,105	)
Our share of equity in and advances to LLCs, net	$	34,994		$	30,492

As of September 30, 2016, and December 31, 2015, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):

	Mortgage Loan Balance (a.)
Name of LLC/LP	9/30/2016		12/31/2015		Maturity Date
FTX MOB Phase II	$	5,333	$	5,427	August, 2017
Grayson Properties		14,496		14,670	September, 2021
Brunswick Associates		8,668		8,798	December, 2024
	$	28,497	$	28,895

(a.)	All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.

Pursuant to the operating and/or partnership agreements of the five LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.

(6) Recent Accounting Pronouncements

In August, 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which adds or clarifies guidance of the classification of certain cash receipts and payments in the statement of cash flows with the intent to alleviate diversity in practice for classifying various types of cash flows. This ASU is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. We are currently evaluating the impact of this ASU on our statement of cash flows.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively

a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASU 2016-02 supersedes the previous leases standard, Leases (Topic 840). The standard is effective on January 1, 2019, with early adoption permitted. We are currently in the process of evaluating the impact the adoption of ASU 2016-02 will have on our financial position or results of operations.

In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs, an update to the accounting standard relating to the presentation of debt issuance costs. Under the new guidance, debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability. In the event that there is not an associated debt liability recorded in the consolidated financial statements, the debt issuance costs will continue to be recorded on the consolidated balance sheet as an asset until the debt liability is recorded. The new standard became effective for the Trust on January 1, 2016. The adoption of this guidance did not have a material impact on our consolidated financial position or results of operations as the update only related to changes in financial statement presentation.

In February 2015, the FASB issued ASU No. 2015-02, Consolidation – Amendments to the Consolidation Analysis, which amends the current consolidation guidance affecting both the variable interest entity (“VIE”) and voting interest entity (“VOE”) consolidation models. The standard does not add or remove any of the characteristics in determining if an entity is a VIE or VOE, but rather enhances the way the Company assesses some of these characteristics. The new standard became effective for the Trust on January 1, 2016 and did not have a material impact on our consolidated financial position or results of operations as none of its existing consolidation conclusions were changed.

In 2014, the FASB issued ASU 2014-09, Revenue From Contracts With Customers (“ASU 2014-09”), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASU 2014-09 states that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment. In 2015, the FASB provided for a one-year deferral of the effective date for ASU 2014-09, which is now effective for us beginning January 1, 2018. We are continuing to evaluate ASU 2014-09 (and related clarifying guidance issued by the FASB); however, we do not expect its adoption to have a significant impact on our consolidated financial statements, as a substantial portion of our revenue consists of rental income from leasing arrangements, which is specifically excluded from ASU 2014-09.

(7) Debt and Financial Instruments

Debt:

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $250 million revolving credit facility, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances pursuant to our ATM equity issuance program. This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit facility borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

On March 27, 2015, we entered into a $185 million revolving credit agreement (“Credit Agreement”) which was amended on May 24, 2016 to, among other things, increase the borrowing capacity to $250 million. The amended Credit Agreement, which is scheduled to mature in March, 2019, includes a $40 million sub limit for letters of credit and a $20 million sub limit for swingline/short-term loans. The Credit Agreement also provides a one-time option to extend the maturity date for an additional one year period, and an option to increase the total facility borrowing capacity up to an additional $50 million, subject to lender agreement. Borrowings under the Credit Agreement are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the Credit Agreement are secured by first priority security interests in and liens on all equity interests in the Trust’s wholly-owned subsidiaries. Borrowings made pursuant to the Credit Agreement will bear interest, at our option, at one, two, three, or six month LIBOR plus an applicable margin ranging from 1.50% to 2.00% or at the Base Rate plus an applicable margin ranging from 0.50% to 1.00%. The Credit Agreement defines “Base Rate” as the greatest of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%. A commitment fee of 0.20% to 0.40% (depending on our total leverage ratio) will be charged on the average

unused portion of the revolving credit commitments. The margins over LIBOR, Base Rate and the commitment fee are based upon our ratio of debt to total capital. At September 30, 2016, the applicable margin over the LIBOR rate was 1.625%, the margin over the Base Rate was 0.625%, and the commitment fee was 0.25%.

At September 30, 2016, we had $192.3 million of outstanding borrowings and $2.7 million of letters of credit outstanding under our Credit Agreement. We had $55.0 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of September 30, 2016. There are no compensating balance requirements.

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at September 30, 2016. We also believe that we would remain in compliance if the full amount of our commitment was borrowed.

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

	Covenant		September 30, 2016
Tangible net worth	$	125,000	$	172,329
Total leverage	< 60%			47.8	%
Secured leverage	< 30%			17.6	%
Unencumbered leverage	< 60%			48.7	%
Fixed charge coverage	> 1.50x		3.7x

As indicated on the following table, we have fourteen mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of September 30, 2016, with a combined outstanding balance of $107.8 million, excluding net debt premium of $132,000 and net of net financing fees of $321,000 (amounts in thousands):

Facility Name	Outstanding Balance (in thousands)(a)		Interest Rate			Maturity Date
Summerlin Hospital Medical Office Building III floating rate mortgage loan (b.)	$	10,462		3.77	%	December, 2016
Peace Health fixed rate mortgage loan (b.)		20,434		5.64	%	April, 2017
Auburn Medical II floating rate mortgage loan (b.)		6,783		3.27	%	April, 2017
Medical Center of Western Connecticut fixed rate mortgage loan (b.)		4,568		6.00	%	June, 2017
Summerlin Hospital Medical Office Building II fixed rate mortgage loan (b.)		11,175		5.50	%	October, 2017
Phoenix Children’s East Valley Care Center fixed rate mortgage loan		6,239		5.88	%	December, 2017
Centennial Hills Medical Office Building floating rate mortgage loan		10,116		3.77	%	January, 2018
Sparks Medical Building/Vista Medical Terrace floating rate mortgage loan		4,260		3.77	%	February, 2018
Rosenberg Children’s Medical Plaza fixed rate mortgage loan		8,190		4.85	%	May, 2018
Vibra Hospital-Corpus Christi fixed rate mortgage loan		2,746		6.50	%	July, 2019
700 Shadow Lane and Goldring MOBs fixed rate mortgage loan		6,294		4.54	%	June, 2022
BRB Medical Office Building fixed rate mortgage loan		6,362		4.27	%	December, 2022
Desert Valley Medical Center fixed rate mortgage loan		5,114		3.62	%	January, 2023
Tuscan Professional Building fixed rate mortgage loan		5,106		5.56	%	June, 2025
Total	$	107,849

(a.)	All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.

(b.)	This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our Credit Agreement.

The mortgages are secured by the real property of the buildings as well as property leases and rents. The mortgages have a combined fair value of approximately $110 million as of September 30, 2016. Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.

At December 31, 2015, we had fourteen mortgages, all of which were non-recourse to us, included in our consolidated balance sheet. The combined outstanding balance of these fourteen mortgages was $110.3 million (excluding net debt premium of $298,000 and net of net financing fees of $398,000), and had a combined fair value of approximately $112 million.

Financial Instruments:

During the third quarter of 2013, we entered into an interest rate cap on a total notional amount of $10 million whereby we paid a premium of $136,000. During the first quarter of 2014, we entered into two additional interest rate cap agreements on a total notional amount of $20 million whereby we paid premiums of $134,500. In exchange for the premium payments, the counterparties agreed to pay us the difference between 1.50% and one-month LIBOR if one-month LIBOR rises above 1.50% during the term of the cap. From inception through September 30, 2016, no payments have been made to us by the counterparties pursuant to the terms of these caps which expire in January, 2017.

During the second quarter of 2016, we entered into an interest rate cap on the total notional amount of $30 million whereby we paid a premium of $115,000. In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.50% and one-month LIBOR if one-month LIBOR rises above 1.50% during the term of the cap. This interest rate cap becomes effective in January, 2017, coinciding with the expiration of the above-mentioned interest rate caps and expires in March, 2019. During the third quarter of 2016, we entered into an additional interest rate cap agreement on a total notional amount of $30 million whereby we paid a premium of $55,000. In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.5% and one-month LIBOR if one-month LIBOR rises above 1.5% during the term of the cap. This interest rate cap became effective in October, 2016 and expires in March, 2019.

(8) Segment Reporting

Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.

Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We are a real estate investment trust (“REIT”) that commenced operations in 1986. We invest in healthcare and human service related facilities currently including acute care hospitals, rehabilitation hospitals, sub-acute facilities, surgery centers, free-standing emergency departments, childcare centers and medical office buildings (“MOBs”). As of September 30, 2016, we have sixty-five real estate investments located in twenty states consisting of:

•

six hospital facilities consisting of three acute care, one rehabilitation and two sub-acute;

•

three free-standing emergency departments (“FEDs”);

•

fifty-two medical/office buildings, including five owned by unconsolidated limited liability companies (“LLCs”), and;

•

four pre-school and childcare centers.

Forward Looking Statements and Certain Risk Factors

You should carefully review all of the information contained in this Quarterly Report, and should particularly consider any risk factors that we set forth in this Quarterly Report and in other reports or documents that we file from time to time with the Securities and Exchange Commission (the “SEC”). In this Quarterly Report, we state our beliefs of future events and of our future financial performance. In some cases, you can identify those so-called “forward-looking statements” by words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “appears,” “projects” and similar expressions, as well as statements in future tense. You should be aware that those statements are only our predictions. Actual events or results may differ materially. In evaluating those statements, you should specifically consider various factors, including the risks outlined herein and in our Annual Report on Form 10-K for the year ended December 31, 2015 in Item 1A Risk Factors and in Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations—Forward Looking Statements. Those factors may cause our actual results to differ materially from any of our forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by which, such performance or results will be achieved. Forward-looking information is based on information available at the time and/or our good faith belief with respect to future events, and is subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Such factors include, among other things, the following:

•

a substantial portion of our revenues are dependent upon one operator, Universal Health Services, Inc. (“UHS”). We cannot assure you that subsidiaries of UHS will renew the leases on our three acute care hospitals (which are scheduled to expire in December, 2021) and two FEDs at existing lease rates or fair market value lease rates. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital facilities upon expiration of the lease terms, our future revenues and results of operations could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to these leases;

•

in certain of our markets, the general real estate market has been unfavorably impacted by increased competition/capacity and decreases in occupancy and rental rates which may adversely impact our operating results and the underlying value of our properties;

•

a number of legislative initiatives have recently been passed into law that may result in major changes in the health care delivery system on a national or state level to the operators of our facilities, including UHS. No assurances can be given that the implementation of these new laws will not have a material adverse effect on the business, financial condition or results of operations of our operators;

•

a subsidiary of UHS is our Advisor and our officers are all employees of a wholly-owned subsidiary of UHS, which may create the potential for conflicts of interest;

•

lost revenues resulting from the exercise of purchase options, lease expirations and renewals, loan repayments and other restructuring;

•

our ability to continue to obtain capital on acceptable terms, including borrowed funds, to fund future growth of our business;

•

the outcome of known and unknown litigation, government investigations, and liabilities and other claims asserted against us or the operators of our facilities;

•

failure of the operators of our hospital facilities to comply with governmental regulations related to the Medicare and Medicaid licensing and certification requirements could have a material adverse impact on our future revenues and the underlying value of the property;

•

the potential unfavorable impact on our business of deterioration in national, regional and local economic and business conditions, including a worsening of credit and/or capital market conditions, which may adversely affect, our ability to obtain capital which may be required to fund the future growth of our business and refinance existing debt with near term maturities;

•

a deterioration in general economic conditions which could result in increases in the number of people unemployed and/or insured and likely increase the number of individuals without health insurance; as a result, the operators of our facilities may experience decreases in patient volumes which could result in decreased occupancy rates at our medical office buildings;

•

a worsening of the economic and employment conditions in the United States could materially affect the business of our operators, including UHS, which may unfavorably impact our future bonus rentals (on the UHS hospital facilities) and may potentially have a negative impact on the future lease renewal terms and the underlying value of the hospital properties;

•

real estate market factors, including without limitation, the supply and demand of office space and market rental rates, changes in interest rates as well as an increase in the development of medical office condominiums in certain markets;

•

government regulations, including changes in the reimbursement levels under the Medicare and Medicaid program resulting from, among other things, the various health care reform initiatives being implemented;

•

there have been several attempts in Congress to repeal or modify various provisions of the Patient Protection and Affordable Care Act (the “PPACA”). We cannot predict whether or not any of these proposed changes to the PPACA will become law and therefore can provide no assurance that changes to the PPACA, as currently implemented, will not have a material adverse effect on the future operating results of the tenants/operators of our properties and, thus, our business;

•

the issues facing the health care industry that affect the operators of our facilities, including UHS, such as: changes in, or the ability to comply with, existing laws and government regulations; unfavorable changes in the levels and terms of reimbursement by third party payors or government programs, including Medicare (including, but not limited to, the potential unfavorable impact of future reductions to Medicare reimbursements resulting from the Budget Control Act of 2011, as discussed below) and Medicaid (most states have reported significant budget deficits that have, in the past, resulted in the reduction of Medicaid funding to the operators of our facilities, including UHS); demographic changes; the ability to enter into managed care provider agreements on acceptable terms; an increase in uninsured and self-pay patients which unfavorably impacts the collectability of patient accounts; decreasing in-patient admission trends; technological and pharmaceutical improvements that may increase the cost of providing, or reduce the demand for, health care, and; the ability to attract and retain qualified medical personnel, including physicians;

•

in August, 2011, the Budget Control Act of 2011 (the “2011 Act”) was enacted into law. The 2011 Act imposed annual spending limits for most federal agencies and programs aimed at reducing budget deficits by $917 billion between 2012 and 2021, according to a report released by the Congressional Budget Office. The 2011 Act provides for new spending on program integrity initiatives intended to reduce fraud and abuse under the Medicare program. Among its other provisions, the law established a bipartisan Congressional committee, known as the Joint Select Committee on Deficit Reduction (the “Joint Committee”), which was tasked with making recommendations aimed at reducing future federal budget deficits by an additional $1.5 trillion over 10 years. The Joint Committee was unable to reach an agreement by the November 23, 2011 deadline and, as a result, across-the-board cuts to discretionary, national defense and Medicare spending were implemented on March 1, 2013 resulting in Medicare payment reductions of up to 2% per fiscal year with a uniform percentage reduction across all Medicare programs. The Bipartisan Budget Act of 2015, enacted on November 2, 2015, continued the 2% reductions to Medicare reimbursement imposed under the 2011 Act. We cannot predict whether Congress will restructure the implemented Medicare payment reductions or what federal other deficit reduction initiatives may be proposed by Congress going forward. We also cannot predict the effect these enactments will have on operators (including UHS), and, thus, our business;

•

in March, 2010, the Health Care and Education Reconciliation Act of 2010 and the Patient Protection and Affordable Care Act were enacted into law and created significant changes to health insurance coverage for U.S. citizens as well as material revisions to the federal Medicare and state Medicaid programs. The two combined primary goals of these acts are to provide for increased access to coverage for healthcare and to reduce healthcare-related expenses. Medicare, Medicaid and other health care industry changes are scheduled to be implemented at various times during this decade. We cannot predict the effect, if any, these enactments will have on operators (including UHS) and, thus, our business;

•

competition for our operators from other REITs;

•

the operators of our facilities face competition from other health care providers, including physician owned facilities and other competing facilities, including certain facilities operated by UHS but the real property of which is not owned by us. Such competition is experienced in markets including, but not limited to, McAllen, Texas, the site of our McAllen Medical Center, a 430-bed acute care hospital, and Riverside County, California, the site of our Southwest Healthcare System-Inland Valley Campus, a 132-bed acute care hospital;

•

changes in, or inadvertent violations of, tax laws and regulations and other factors than can affect REITs and our status as a REIT;

•

should we be unable to comply with the strict income distribution requirements applicable to REITs, utilizing only cash generated by operating activities, we would be required to generate cash from other sources which could adversely affect our financial condition;

•

our ownership interests in five LLCs/LPs in which we hold non-controlling equity interests. In addition, pursuant to the operating and/or partnership agreements of the five entities in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member;

•

fluctuations in the value of our common stock, and;

•

other factors referenced herein or in our other filings with the Securities and Exchange Commission.

Given these uncertainties, risks and assumptions, you are cautioned not to place undue reliance on such forward-looking statements. Our actual results and financial condition, including the operating results of our lessees and the facilities leased to subsidiaries of UHS, could differ materially from those expressed in, or implied by, the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. We assume no obligation to publicly update any forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except as may be required by law. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes.

We consider our critical accounting policies to be those that require us to make significant judgments and estimates when we prepare our financial statements, including the following:

Revenue Recognition: Our revenues consist primarily of rentals received from tenants, which are comprised of minimum rent (base rentals), bonus rentals and reimbursements from tenants for their pro-rata share of expenses such as common area maintenance costs, real estate taxes and utilities.

The minimum rent for all hospital facilities is fixed over the initial term or renewal term of the respective leases. Rental income recorded by our properties, including our consolidated and unconsolidated MOBs, relating to leases in excess of one year in length, is recognized using the straight-line method under which contractual rents are recognized evenly over the lease term regardless of when payments are due. The amount of rental revenue resulting from straight-line rent adjustments is dependent on many factors including the nature and amount of any rental concessions granted to new tenants, stipulated rent increases under existing leases, as well as the acquisitions and sales of properties that have existing in-place leases with terms in excess of one year. As a result, the straight-line adjustments to rental revenue may vary from period-to-period. Bonus rents are recognized when earned based upon increases in each facility’s net revenue in excess of stipulated amounts. Bonus rentals are determined and paid each quarter based upon a computation

that compares the respective facility’s current quarter’s net revenue to the corresponding quarter in the base year. Tenant reimbursements for operating expenses are accrued as revenue in the same period the related expenses are incurred.

Real Estate Investments: On the date of acquisition, the purchase price of a property is allocated to the property’s land, buildings and intangible assets based upon our estimates of their fair values. Depreciation is computed using the straight-line method over the useful lives of the buildings and capital improvements. The value of intangible assets is amortized over the remaining lease term.

Asset Impairment: Real estate investments and related intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the property might not be recoverable. A property to be held and used is considered impaired only if management’s estimate of the aggregate future cash flows, less estimated capital expenditures, to be generated by the property, undiscounted and without interest charges, are less than the carrying value of the property. This estimate takes into consideration factors such as expected future operating income, trends and prospects, as well as the effects of demand, competition, local market conditions and other factors.

The determination of undiscounted cash flows requires significant estimates by management, including the expected course of action at the balance sheet date that would lead to such cash flows. Subsequent changes in estimated undiscounted cash flows arising from changes in anticipated action to be taken with respect to the property could impact the determination of whether an impairment exists and whether the effects could materially impact our net income. To the extent estimated undiscounted cash flows are less than the carrying value of the property, the loss will be measured as the excess of the carrying amount of the property over the fair value of the property.

Assessment of the recoverability by us of certain lease related costs must be made when we have reason to believe that a tenant might not be able to perform under the terms of the lease as originally expected. This requires us to make estimates as to the recoverability of such costs. If we determine that the intangible assets are not recoverable from future cash flows, the excess of carrying value of the intangible asset over its estimated fair value is charged to income.

An other than temporary impairment of an investment in an LLC is recognized when the carrying value of the investment is not considered recoverable based on evaluation of the severity and duration of the decline in value, including projected declines in cash flow. To the extent impairment has occurred, the excess carrying value of the asset over its estimated fair value is charged to income.

Federal Income Taxes: No provision has been made for federal income tax purposes since we qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986, and intend to continue to remain so qualified. As such, we are exempt from federal income taxes and we are required to distribute at least 90% of our real estate investment taxable income to our shareholders.

We are subject to a federal excise tax computed on a calendar year basis. The excise tax equals 4% of the amount by which 85% of our ordinary income plus 95% of any capital gain income for the calendar year exceeds cash distributions during the calendar year, as defined. No provision for excise tax has been reflected in the financial statements as no tax is expected to be due.

Earnings and profits, which determine the taxability of dividends to shareholders, will differ from net income reported for financial reporting purposes due to the differences for federal tax purposes in the cost basis of assets and in the estimated useful lives used to compute depreciation and the recording of provision for investment losses.

Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions—UHS is our principal tenant and through UHS of Delaware, Inc., a wholly owned subsidiary of UHS, serves as our advisor (the “Advisor”) under an Advisory Agreement dated December 24, 1986 between the Advisor and us (the “Advisory Agreement”). Our officers are all employees of UHS (through UHS of Delaware, Inc.) and although as of September 30, 2016 we had no salaried employees, our officers do receive stock-based compensation from time-to-time.

Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory. In December of 2015, based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the Advisory Agreement was renewed for 2016 pursuant to the same terms as the Advisory Agreement in place during 2015.

The combined revenues generated from the leases on the UHS hospital facilities comprised approximately 23% and 25% of our consolidated revenues for the three months ended September 30, 2016 and 2015, respectively, and approximately 24% and 25% of our consolidated revenues for the nine months ended September 30, 2016 and 2015, respectively. Including 100% of the revenues generated at the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%, the leases on the UHS hospital facilities accounted for approximately 19% and 20% of the combined consolidated and unconsolidated revenue for the three months ended September 30, 2016 and 2015, respectively, and approximately 20% of the combined consolidated and unconsolidated revenue for each of the nine months ended September 30, 2016 and 2015. In addition, seventeen MOBs, including one currently under construction, and FEDs, that are either wholly or jointly-owned by UHT, include or will include tenants which are subsidiaries of UHS.

Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of all hospital properties with subsidiaries of UHS, UHS has the option to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities at the end of the lease terms or any renewal terms at the appraised fair market value. In addition, the Master Lease, as amended during 2006, includes a change of control provision whereby UHS has the right, upon one month’s notice should a change of control of the Trust occur, to purchase any or all of the three leased hospital properties at their appraised fair market value. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer. The leases related to the hospital facilities of UHS are guaranteed by UHS and cross-defaulted with one another.

In June, 2016, three wholly-owned subsidiaries of UHS provided the required notice to us, exercising the 5-year renewal options on the leases related to our acute care hospitals (McAllen Medical Center, Wellington Regional Medical Center and Southwest Healthcare System, Inland Valley Campus). The renewals extended the lease terms on these facilities, at existing lease rates, to December, 2021. Please see Footnote 2, “Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions” for additional information.

Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of September 30, 2016 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.

For additional disclosure related to our relationship with UHS, please refer to Note 2 to the condensed consolidated financial statements, Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions.

Results of Operations

During the three-month period ended September 30, 2016, net income increased to $3.8 million, as compared to $3.6 million during the third quarter of 2015. The $179,000 net increase was attributable to $510,000 of combined favorable changes partially offset by the $331,000 of transaction costs incurred during the third quarter of 2016.

During the nine-month period ended September 30, 2016, net income decreased $6.6 million to $12.8 million, as compared to $19.3 million during the first nine months of 2015. The net decrease was primarily attributable to:

•

an $8.7 million decrease due to the gain on property exchange recorded during the first nine months of 2015;

•

a decrease caused by increased transaction costs;

•

a decrease caused by an increase in interest expense due in part to the borrowings utilized to finance the acquisitions in 2016;

•

an increase due to increased net income generated at various properties, including the favorable impact resulting from the property-exchange transaction completed during the second quarter of 2015, and;

•

increased net income resulting from the above-mentioned repayment during the fourth quarter of 2015 of a previously outstanding third-party mortgage of an unconsolidated LLC utilizing funds borrowed under our revolving credit facility.

Included in our other operating expenses are expenses related to the consolidated medical office buildings, which totaled $4.1 million and $3.9 million for the three-month periods ended September 30, 2016 and 2015, respectively, and $12.1 million and $12.6 million for the nine-month periods ended September 30, 2016 and 2015, respectively. A large portion of the expenses associated with our consolidated medical office buildings is passed on directly to the tenants either directly as tenant reimbursements of common area maintenance expenses or included in base rental amounts. Tenant reimbursements for operating expenses are accrued as revenue in the same period the related expenses are incurred and are included as tenant reimbursement revenue in our condensed consolidated statements of income.

Funds from operations (“FFO”) is a widely recognized measure of performance for Real Estate Investment Trusts (“REITs”). We believe that FFO and FFO per diluted share, which are non-GAAP financial measures (“GAAP” is Generally Accepted Accounting Principles in the United States of America), are helpful to our investors as measures of our operating performance. We compute FFO, as reflected below, in accordance with standards established by the National Association of Real Estate Investment Trusts (“NAREIT”), which may not be comparable to FFO reported by other REITs that do not compute FFO in accordance with the NAREIT definition, or that interpret the NAREIT definition differently than we interpret the definition. FFO do not represent cash generated from operating activities in accordance with GAAP and should not be considered to be an alternative to net income determined in accordance with GAAP. In addition, FFO should not be used as: (i) an indication of our financial performance determined in accordance with GAAP; (ii) an alternative to cash flow from operating activities determined in accordance with GAAP; (iii) a measure of our liquidity, or; (iv) an indicator of funds available for our cash needs, including our ability to make cash distributions to shareholders.

Below is a reconciliation of our reported net income to FFO for the three and nine-month periods ended September 30, 2016 and 2015 (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Net income	$	3,818	$	3,639	$	12,769	$	19,339
Depreciation and amortization expense on consolidated investments		5,781		5,332		16,549		16,520
Depreciation and amortization expense on unconsolidated affiliates		463		433		1,378		1,261
Gain on property exchange		-		-		-		(8,742	)
Funds From Operations	$	10,062	$	9,404	$	30,696	$	28,378
Weighted average number of shares and equivalents outstanding - Diluted		13,575		13,302		13,431		13,297
Funds From Operations per diluted share	$	0.74	$	0.71	$	2.29	$	2.13

Our FFO increased to $10.1 million during the three-month period ended September 30, 2016, as compared to $9.4 million during the comparable quarter of 2015. The $658,000 increase in FFO during the third quarter of 2016, as compared to the third quarter of 2015, was attributable to: (i) a $179,000 increase in net income, as discussed above, plus,; (ii) $479,000 net increase in the add back of depreciation and amortization expense incurred at our properties on a consolidated and unconsolidated basis.

Our FFO increased to $30.7 million during the nine-month period ended September 30, 2016, as compared to $28.4 million during the comparable period of 2015. The $2.3 million increase in FFO during the nine-month period ended September 30, 2016, as compared to the comparable period of 2015, was attributable to: (i) a $6.6 million decrease in net income, as discussed above, offset by; (ii) the $8.7 million gain recorded during the second quarter of 2015, which was deducted for FFO purposes, less; (iii) $146,000 net increase in the add back of depreciation and amortization expense incurred at our properties on a consolidated and unconsolidated basis.

Liquidity and Capital Resources

Net cash provided by operating activities

Net cash provided by operating activities was $29.8 million during the nine-month period ended September 30, 2016 as compared to $27.3 million during the comparable period of 2015. The $2.5 million net increase was attributable to:

•

a favorable change of $2.2 million due to an increase in net income plus/minus the adjustments to reconcile net income to net cash provided by operating activities (depreciation and amortization, amortization of debt premium, stock-based compensation and gain on property exchange), as discussed above in Results of Operations, and;

•

other combined net favorable changes of $266,000.

Net cash used in investing activities

Net cash used in investing activities was $64.2 million during the nine months ended September 30, 2016 as compared to $19.9 million during the nine months ended September 30, 2015.

During the nine-month period ended September 30, 2016, we funded: (i) $5.5 million in equity investments in various unconsolidated LLCs, including $4.8 million to purchase an additional 10% equity interest in the Arlington Medical Plaza LLC, as discussed above; (ii) $7.1 million in capital additions to real estate investments primarily related to tenant improvements at various MOBs as well as construction in progress costs for the Henderson Medical Plaza MOB, as discussed above; (iii) $420,000 consisting of a deposit on real estate assets, and; (iv) $52.2 million to acquire the real estate assets of three properties, as discussed above. In addition, during the nine-month period ended September 30, 2016, we received: (i) $634,000 of installment repayments of an outstanding member loan advanced to an unconsolidated LLC, and; (ii) $318,000 of cash distributions in excess of income received from our unconsolidated LLCs.

During the nine-month period ended September 30, 2015, we funded: (i) $418,000 in equity investments in various unconsolidated LLCs; (ii) $3.7 million in capital additions to real estate investments primarily for tenant improvements at various MOBs; (iii) $16.8 million to acquire the real estate assets of a medical office building and two free-standing emergency departments, and; (iv) $2.3 million payment of a note payable related to the purchase of third-party minority ownership interests in six majority-owned LLCs during the third quarter of 2014. In addition, during the nine-month period ended September 30, 2015, we received: (i) $168,000 of cash distributions in excess of income from our unconsolidated LLCs; (ii) $1.1 million of cash proceeds in connection with the refinancing of third-party debt by a majority-owned LLC in which we hold a noncontrolling ownership interest, and; (iii) $2.0 million of cash proceeds in connection with the property exchange with an unrelated third party.

Net cash provided by/(used in) financing activities

Net cash provided by financing activities was $34.6 million during the nine months ended September 30, 2016, as compared to $7.6 million of net cash used in financing activities during the nine months ended September 30, 2015.

During the nine-month period ended September 30, 2016, we: (i) received $50.1 million of additional net borrowings on our revolving line of credit, and; (ii) received $13.4 million of net cash from the issuance of shares of beneficial interest (as discussed below). Additionally, during the nine months ended September 30, 2016, we paid: (i) $2.4 million on mortgages and other notes payable that are non-recourse to us; (ii) $307,000 of financing costs paid related to the amendment of our revolving credit facility; (iii) $26.2 million of dividends, and (iv) $30,000 of partial settlements of dividend equivalent rights.

During the nine-month period ended September 30, 2015, we: (i) received $24.6 million of additional net borrowings on our revolving line of credit, and; (ii) received $1.7 million of net cash from the issuance of shares of beneficial interest ($1.1 million relates to shares

issued in late December, 2014, as discussed below). Additionally, during the nine months ended September 30, 2015, we paid: (i) $7.4 million on mortgages and other notes payable that are non-recourse to us, (including the pay-off of the $4.9 million outstanding mortgage on the Spring Valley Medical Office Building utilizing funds borrowed under our revolving credit facility); (ii) $1.0 million of financing costs paid on the revolving credit facility; (iii) $25.5 million of dividends, and (iv) $17,000 of partial settlements of dividend equivalent rights.

During the second quarter of 2016, we recommenced an at-the-market (“ATM”) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of approximately $23.3 million to or through Merrill Lynch, Pierce, Fenner and Smith, Incorporated (“Merrill Lynch”), as sales agent and/or principal. The common shares were offered pursuant to the Registration Statement filed with the Securities and Exchange Commission, which became effective during the fourth quarter of 2015.

During the first nine months of 2016, pursuant to the ATM Program, we issued 249,016 shares at an average price of $55.30 per share (all of which were issued during the second quarter) which generated approximately $13.2 million of net cash proceeds (net of approximately $558,000, consisting of compensation of approximately $344,000 to Merrill Lynch as well as $214,000 of other various fees and expenses). As of September 30, 2016, we had approximately $9.5 million of gross proceeds still available for issuance under the program. Since inception of the program through September, 2016, we have issued 829,916 shares at an average price of $48.77 per share, which generated approximately $38.8 million of net proceeds (net of approximately $1.7 million, consisting of compensation of $1.0 million to Merrill Lynch as well as $680,000 of other various fees and expenses). We have, and intend, to use the proceeds generated pursuant to the ATM program to reduce amounts outstanding under our revolving credit agreement. After such repayment of debt, we may re-borrow funds under our revolving credit agreement for general operating purposes, including working capital, capital expenditures, acquisitions, dividend payments and the refinance of third-party debt.

Additional cash flow and dividends paid information for the nine-month periods ended September 30, 2016 and 2015:

As indicated on our condensed consolidated statement of cash flows, we generated net cash provided by operating activities of $29.8 million and $27.3 million during the nine-month periods ended September 30, 2016 and 2015, respectively. As also indicated on our statement of cash flows, noncash expenses including depreciation and amortization, amortization of debt premium, stock-based compensation and the gain recorded during the first nine months of 2015 are the primary differences between our net income and net cash provided by operating activities during each period. In addition, as reflected in the cash flows from investing activities section, we received $318,000 and $168,000 during the nine- month periods ended September 30, 2016 and 2015, respectively, of cash distributions in excess of income from various unconsolidated LLCs which represents our share of the net cash flow distributions from these entities. The cash distributions in excess of income represent operating cash flows net of capital expenditures and debt repayments made by the LLCs.

We generated $30.1 million and $27.5 million of net cash during the nine months ended September 30, 2016 and 2015, respectively, related to the operating activities of our properties recorded on a consolidated and an unconsolidated basis. We paid dividends of $26.2 million and $25.5 million during the nine months ended September 30, 2016 and 2015, respectively. During the first nine months of 2016, the $30.1 million of net cash generated related to the operating activities of our properties was approximately $3.8 million greater than the $26.2 million of dividends paid during the nine-month period. During the first nine months of 2015, the $27.5 million of net cash generated related to the operating activities of our properties was approximately $2.0 million greater than the $25.5 million of dividends paid during the nine-month period.

As indicated in the cash flows from investing activities and cash flows from financing activities sections of the statements of cash flows, there were various other sources and uses of cash during the nine months ended September 30, 2016 and 2015. From time to time, various other sources and uses of cash may include items such as investments and advances made to/from LLCs, additions to real estate investments, acquisitions/divestiture of properties, net borrowings/repayments of debt, and proceeds generated from the issuance of equity. Therefore, in any given period, the funding source for our dividend payments is not wholly dependent on the operating cash flow generated by our properties. Rather, our dividends as well as our capital reinvestments into our existing properties, acquisitions of real property and other investments are funded based upon the aggregate net cash inflows or outflows from all sources and uses of cash from the properties we own either in whole or through LLCs, as outlined above.

In determining and monitoring our dividend level on a quarterly basis, our management and Board of Trustees consider many factors in determining the amount of dividends to be paid each period. These considerations primarily include: (i) the minimum required amount of dividends to be paid in order to maintain our REIT status; (ii) the current and projected operating results of our properties, including those owned in LLCs, and; (iii) our future capital commitments and debt repayments, including those of our LLCs. Based upon the information discussed above, as well as consideration of projections and forecasts of our future operating cash flows, management and the Board of Trustees have determined that our operating cash flows have been sufficient to fund our dividend

payments. Future dividend levels will be determined based upon the factors outlined above with consideration given to our projected future results of operations.

We expect to finance all capital expenditures and acquisitions and pay dividends utilizing internally generated and additional funds. Additional funds may be obtained through: (i) borrowings under our existing $250 million revolving credit facility agreement (which has $55.0 million of available borrowing capacity, net of outstanding borrowings and letters of credit, as of September 30, 2016); (ii) the issuance of equity pursuant to an ATM equity issuance program; (iii) borrowings under or refinancing of existing third-party debt pursuant to mortgage loan agreements entered into by our LLCs, and/or; (iv) the issuance of other long-term debt.

We believe that our operating cash flows, cash and cash equivalents, available borrowing capacity under our revolving credit facility and access to the capital markets provide us with sufficient capital resources to fund our operating, investing and financing requirements for the next twelve months, including providing sufficient capital to allow us to make distributions necessary to enable us to continue to qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986. In the event we need to access the capital markets or other sources of financing, there can be no assurance that we will be able to obtain financing on acceptable terms or within an acceptable time. Our inability to obtain financing on terms acceptable to us could have a material unfavorable impact on our results of operations, financial condition and liquidity.

Credit facilities and mortgage debt

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

	Covenant		September 30, 2016
Tangible net worth	$	125,000	$	172,329
Total leverage	< 60%			47.8	%
Secured leverage	< 30%			17.6	%
Unencumbered leverage	< 60%			48.7	%
Fixed charge coverage	> 1.50x		3.7x

Facility Name	Outstanding Balance (in thousands)(a)		Interest Rate			Maturity Date
Summerlin Hospital Medical Office Building III floating rate mortgage loan (b.)	$	10,462		3.77	%	December, 2016
Peace Health fixed rate mortgage loan (b.)		20,434		5.64	%	April, 2017
Auburn Medical II floating rate mortgage loan (b.)		6,783		3.27	%	April, 2017
Medical Center of Western Connecticut fixed rate mortgage loan (b.)		4,568		6.00	%	June, 2017
Summerlin Hospital Medical Office Building II fixed rate mortgage loan (b.)		11,175		5.50	%	October, 2017
Phoenix Children’s East Valley Care Center fixed rate mortgage loan		6,239		5.88	%	December, 2017
Centennial Hills Medical Office Building floating rate mortgage loan		10,116		3.77	%	January, 2018
Sparks Medical Building/Vista Medical Terrace floating rate mortgage loan		4,260		3.77	%	February, 2018
Rosenberg Children’s Medical Plaza fixed rate mortgage loan		8,190		4.85	%	May, 2018
Vibra Hospital-Corpus Christi fixed rate mortgage loan		2,746		6.50	%	July, 2019
700 Shadow Lane and Goldring MOBs fixed rate mortgage loan		6,294		4.54	%	June, 2022
BRB Medical Office Building fixed rate mortgage loan		6,362		4.27	%	December, 2022
Desert Valley Medical Center fixed rate mortgage loan		5,114		3.62	%	January, 2023
Tuscan Professional Building fixed rate mortgage loan		5,106		5.56	%	June, 2025
Total	$	107,849

(a.)	All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.

(b.)	This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our Credit Agreement.

Off Balance Sheet Arrangements

As of September 30, 2016, we are party to certain off balance sheet arrangements consisting of standby letters of credit and equity and debt financing commitments. Our outstanding letters of credit at September 30, 2016 totaled $2.7 million consisting of: (i) $1.7 million related to Centennial Hills Medical Properties; (ii) $380,000 related to FTX MOB Phase II, LP, and; (iii) $650,000 related to Banburry Medical Properties.

Acquisition and Divestiture Activity

Please see Note 4 to the condensed consolidated financial statements for completed transactions.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Reference is made to Item 7A in our Annual Report on Form 10-K for the year ended December 31, 2015. There have been no material changes in the quantitative and qualitative disclosures during the first nine months of 2016.

Item 4. Controls and Procedures

As of September 30, 2016, under the supervision and with the participation of our management, including the Trust’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), we performed an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) or Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “1934 Act”).

Based on this evaluation, the CEO and CFO have concluded that our disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the 1934 Act and the SEC rules thereunder.

There have been no changes in our internal control over financial reporting or in other factors during the first nine months of 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

UNIVERSAL HEALTH REALTY INCOME TRUST

Item 1A. Risk Factors

Our Annual Report on Form 10-K for the year ended December 31, 2015 includes a listing of risk factors to be considered by investors in our securities. There have been no material changes in our risk factors from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2015.

Item 6. Exhibits

(a.) Exhibits:

31.1		Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

31.2		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

32.1		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 8, 2016		UNIVERSAL HEALTH REALTY INCOME TRUST (Registrant)

		/s/ Alan B. Miller
		Alan B. Miller,
		Chairman of the Board, President and Chief Executive Officer (Principal Executive Officer)

		/s/ Charles F. Boyle
		Charles F. Boyle, Vice President and Chief Financial Officer (Principal Financial Officer)

EXHIBIT INDEX

Exhibit No.		Description

31.1		Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

31.2		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

32.1		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

EX-31.1 2 uht-ex311_6.htm EX-31.1 uht-ex311_6.htm

Exhibit 31.1

CERTIFICATION—Chief Executive Officer

I, Alan B. Miller, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Universal Health Realty Income Trust;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 8, 2016

/s/ Alan B. Miller

President and Chief Executive Officer

EX-31.2 3 uht-ex312_9.htm EX-31.2 uht-ex312_9.htm

Exhibit 31.2

CERTIFICATION—Chief Financial Officer

I, Charles F. Boyle, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Universal Health Realty Income Trust;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 8, 2016

/s/ Charles F. Boyle

Vice President and Chief Financial Officer

EX-32.1 4 uht-ex321_8.htm EX-32.1 uht-ex321_8.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Universal Health Realty Income Trust (the “Trust”) on Form 10-Q for the quarter ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan B. Miller, President and Chief Executive Officer of the Trust, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Trust at the end of, and for the period covered by, the Report.

/s/ Alan B. Miller

President and Chief Executive Officer

November 8, 2016

A signed original of this written statement required by Section 906 has been provided to the Trust and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 uht-ex322_7.htm EX-32.2 uht-ex322_7.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Universal Health Realty Income Trust (the “Trust”) on Form 10-Q for the quarter ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Charles F. Boyle, Vice President and Chief Financial Officer of the Trust, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

/s/ Charles F. Boyle

Vice President and Chief Financial Officer

November 8, 2016

EX-101.INS 6 uht-20160930.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure uht:Property uht:Time uht:Subsidiary uht:RenewalOption utr:sqft uht:Building uht:Option uht:MortgageLoan uht:Derivative uht:Segment 0000798783 2016-01-01 2016-09-30 0000798783 2016-10-31 0000798783 2016-07-01 2016-09-30 0000798783 2015-07-01 2015-09-30 0000798783 2015-01-01 2015-09-30 0000798783 2016-09-30 0000798783 2015-12-31 0000798783 2014-12-31 0000798783 2015-09-30 0000798783 us-gaap:MinimumMember uht:UnconsolidatedLimitedLiabilitiesMember 2016-09-30 0000798783 us-gaap:MaximumMember uht:UnconsolidatedLimitedLiabilitiesMember 2016-09-30 0000798783 uht:MedicalOfficeBuildingsMember uht:LimitedLiabilityCompanyOrLimitedPartnerMember 2016-09-30 0000798783 uht:UniversalHealthServicesIncMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0000798783 uht:UniversalHealthServicesIncMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0000798783 uht:UniversalHealthServicesIncMember 2016-09-30 0000798783 uht:UniversalHealthServicesIncMember 2016-01-01 2016-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2016-07-01 2016-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2015-07-01 2015-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2016-01-01 2016-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2015-01-01 2015-09-30 0000798783 uht:CombinedMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2016-07-01 2016-09-30 0000798783 uht:CombinedMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2015-07-01 2015-09-30 0000798783 uht:CombinedMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2016-01-01 2016-09-30 0000798783 uht:CombinedMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2015-01-01 2015-09-30 0000798783 uht:UniversalHealthServicesIncMember 2016-06-01 2016-06-30 0000798783 uht:McAllenMedicalCenterMember 2016-09-30 0000798783 uht:WellingtonRegionalMedicalCenterMember 2016-09-30 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember 2016-09-30 0000798783 uht:McAllenMedicalCenterMember 2016-01-01 2016-09-30 0000798783 uht:WellingtonRegionalMedicalCenterMember 2016-01-01 2016-09-30 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember 2016-01-01 2016-09-30 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2016-01-01 2016-09-30 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember uht:UniversalHealthServicesIncMember 2016-01-01 2016-09-30 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember us-gaap:MinimumMember uht:UniversalHealthServicesIncMember 2016-01-01 2016-09-30 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember us-gaap:MaximumMember uht:UniversalHealthServicesIncMember 2016-01-01 2016-09-30 0000798783 uht:HendersonMedicalPlazaMember uht:UniversalHealthServicesIncMember 2016-03-31 0000798783 uht:HendersonMedicalPlazaMember uht:UniversalHealthServicesIncMember 2016-01-01 2016-03-31 0000798783 uht:HendersonMedicalPlazaMember uht:UniversalHealthServicesIncMember 2016-09-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2016-09-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember us-gaap:MinimumMember 2016-09-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2016-01-01 2016-09-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2015-01-01 2015-09-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2016-07-01 2016-09-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2015-07-01 2015-09-30 0000798783 uht:UniversalHealthServicesIncMember 2015-12-31 0000798783 2016-06-30 0000798783 uht:AtMarketATMProgramsMember 2016-01-01 2016-09-30 0000798783 uht:AtMarketATMProgramsMember 2013-10-01 2016-09-30 0000798783 uht:AtMarketATMProgramsMember 2016-04-01 2016-06-30 0000798783 uht:AtMarketATMProgramsMember us-gaap:OtherExpenseMember 2016-01-01 2016-09-30 0000798783 uht:AtMarketATMProgramsMember us-gaap:OtherExpenseMember 2013-10-01 2016-09-30 0000798783 uht:FrederickMemorialHospitalCrestwoodMember 2016-07-01 2016-09-30 0000798783 uht:FrederickMemorialHospitalCrestwoodMember 2016-09-30 0000798783 uht:FrederickMemorialHospitalCrestwoodMember us-gaap:LeaseAgreementsMember 2016-07-01 2016-09-30 0000798783 uht:ChandlerCorporateCenterIIIMember 2016-04-01 2016-06-30 0000798783 uht:ChandlerCorporateCenterIIIMember 2016-06-30 0000798783 uht:ChandlerCorporateCenterIIIMember us-gaap:LeaseAgreementsMember 2016-04-01 2016-06-30 0000798783 uht:MadisonProfessionalOfficeBuildingMember 2016-01-01 2016-03-31 0000798783 uht:MadisonProfessionalOfficeBuildingMember 2015-01-01 2015-12-31 0000798783 uht:MadisonProfessionalOfficeBuildingMember 2016-03-31 0000798783 us-gaap:LeaseAgreementsMember uht:MadisonProfessionalOfficeBuildingMember 2016-01-01 2016-03-31 0000798783 us-gaap:MinimumMember 2016-01-01 2016-09-30 0000798783 us-gaap:MaximumMember 2016-01-01 2016-09-30 0000798783 uht:SheffieldMedicalBuildingMember 2015-05-31 0000798783 uht:SheffieldMedicalBuildingMember 2015-05-01 2015-05-31 0000798783 uht:SheffieldMedicalBuildingMember 2015-01-01 2015-09-30 0000798783 uht:HaasMedicalOfficeParkMember 2015-02-01 2015-02-28 0000798783 uht:HaasMedicalOfficeParkMember 2015-02-28 0000798783 uht:WhollyOwnedSubsidiariesOfUHSRealPropertyOfTwoNewlyConstructedAndRecentlyOpenedFEDsLocatedInWeslacoAndMissionTexasMember 2015-01-01 2015-02-28 0000798783 uht:WhollyOwnedSubsidiariesOfUHSRealPropertyOfTwoNewlyConstructedAndRecentlyOpenedFEDsLocatedInWeslacoAndMissionTexasMember uht:RecentlyOpenedFreeStandingEmergencyDepartmentsMember uht:WeslacoMember 2015-02-28 0000798783 uht:WhollyOwnedSubsidiariesOfUHSRealPropertyOfTwoNewlyConstructedAndRecentlyOpenedFEDsLocatedInWeslacoAndMissionTexasMember uht:RecentlyOpenedFreeStandingEmergencyDepartmentsMember uht:MissionMember 2015-02-28 0000798783 uht:WhollyOwnedSubsidiariesOfUHSRealPropertyOfTwoNewlyConstructedAndRecentlyOpenedFEDsLocatedInWeslacoAndMissionTexasMember 2015-01-01 2015-09-30 0000798783 us-gaap:MinimumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2016-09-30 0000798783 us-gaap:MaximumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2016-09-30 0000798783 uht:ArlingtonMedicalPropertiesMember 2016-09-30 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2016-09-30 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2016-09-30 0000798783 uht:ArlingtonMedicalPropertiesMember us-gaap:EquityMethodInvestmentsMember 2016-09-30 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2016-09-30 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2016-09-30 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2016-01-01 2016-09-30 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2016-01-01 2016-09-30 0000798783 uht:ArlingtonMedicalPropertiesMember us-gaap:EquityMethodInvestmentsMember 2016-01-01 2016-09-30 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2016-01-01 2016-09-30 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2016-01-01 2016-09-30 0000798783 uht:BrunswickAssociatesMember 2016-09-30 0000798783 uht:ArlingtonMedicalPropertiesMember 2016-09-30 0000798783 uht:ArlingtonMedicalPropertiesMember 2015-10-01 2015-12-31 0000798783 uht:ArlingtonMedicalPropertiesMember 2016-01-01 2016-09-30 0000798783 uht:GraysonPropertiesMember 2016-09-30 0000798783 uht:FTXMobPhaseTwoLPMember 2016-09-30 0000798783 uht:ArlingtonMedicalPropertiesMember 2016-07-01 2016-09-30 0000798783 uht:ArlingtonMedicalPropertiesMember 2016-01-01 2016-09-30 0000798783 uht:ArlingtonMedicalPropertiesMember 2015-07-01 2015-09-30 0000798783 uht:ArlingtonMedicalPropertiesMember 2015-01-01 2015-09-30 0000798783 uht:ArlingtonMedicalPropertiesMember 2015-01-01 2015-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FtxMobPhaseTwoMember 2016-09-30 0000798783 us-gaap:EquityMethodInvestmentsMember 2016-09-30 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FtxMobPhaseTwoMember 2015-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:GraysonPropertiesMember 2015-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:BrunswickAssociatesMember 2015-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember 2015-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FtxMobPhaseTwoMember 2016-01-01 2016-09-30 0000798783 uht:RevolvingCreditAgreementMember 2015-03-27 0000798783 uht:RevolvingCreditAgreementMember 2016-05-24 0000798783 uht:RevolvingCreditAgreementMember 2015-03-26 2015-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LetterOfCreditMember 2015-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:ShortTermDebtMember 2015-03-27 0000798783 uht:RevolvingCreditAgreementMember 2016-01-01 2016-09-30 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:MinimumMember 2015-03-26 2015-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:MaximumMember 2015-03-26 2015-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:BaseRateMember us-gaap:MinimumMember 2015-03-26 2015-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:BaseRateMember us-gaap:MaximumMember 2015-03-26 2015-03-27 0000798783 uht:RevolvingCreditAgreementMember uht:FederalFundsEffectiveRateMember us-gaap:MinimumMember 2015-03-26 2015-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:MinimumMember 2015-03-26 2015-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:MaximumMember 2015-03-26 2015-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-09-29 2016-09-30 0000798783 uht:RevolvingCreditAgreementMember us-gaap:BaseRateMember 2016-09-29 2016-09-30 0000798783 uht:RevolvingCreditAgreementMember 2016-09-29 2016-09-30 0000798783 us-gaap:MaximumMember 2016-09-30 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeMortgageLoanMember 2016-09-30 0000798783 uht:PeaceHealthMedicalClinicFixedRateMortgageLoanMember 2016-09-30 0000798783 uht:AuburnMedicalTwoMortgageLoanMember 2016-09-30 0000798783 uht:MedicalCenterOfWesternConnecticutFixedRateMortgageLoanMember 2016-09-30 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingTwoMortgageLoanMember 2016-09-30 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2016-09-30 0000798783 uht:CentennialHillsMedicalOfficeBuildingOneMortgageLoanMember 2016-09-30 0000798783 uht:LomaVistaMedicalIncMember 2016-09-30 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember 2016-09-30 0000798783 uht:VibraHospitalOfCorpusChristiFixedRateMortgageLoanMember 2016-09-30 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingMortgageLoanMember 2016-09-30 0000798783 uht:BRBMedicalOfficeBuildingMortgageLoanMember 2016-09-30 0000798783 uht:DesertValleyMedicalCenterFloatingRateMortgageLoanMember 2016-09-30 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2016-09-30 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeMortgageLoanMember 2016-01-01 2016-09-30 0000798783 uht:PeaceHealthMedicalClinicFixedRateMortgageLoanMember 2016-01-01 2016-09-30 0000798783 uht:AuburnMedicalTwoMortgageLoanMember 2016-01-01 2016-09-30 0000798783 uht:MedicalCenterOfWesternConnecticutFixedRateMortgageLoanMember 2016-01-01 2016-09-30 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingTwoMortgageLoanMember 2016-01-01 2016-09-30 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2016-01-01 2016-09-30 0000798783 uht:CentennialHillsMedicalOfficeBuildingOneMortgageLoanMember 2016-01-01 2016-09-30 0000798783 uht:LomaVistaMedicalIncMember 2016-01-01 2016-09-30 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember 2016-01-01 2016-09-30 0000798783 uht:VibraHospitalOfCorpusChristiFixedRateMortgageLoanMember 2016-01-01 2016-09-30 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingMortgageLoanMember 2016-01-01 2016-09-30 0000798783 uht:BRBMedicalOfficeBuildingMortgageLoanMember 2016-01-01 2016-09-30 0000798783 uht:DesertValleyMedicalCenterFloatingRateMortgageLoanMember 2016-01-01 2016-09-30 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2016-01-01 2016-09-30 0000798783 us-gaap:InterestRateCapMember 2013-09-30 0000798783 us-gaap:InterestRateCapMember 2014-03-31 0000798783 us-gaap:InterestRateCapMember 2016-06-30 0000798783 us-gaap:InterestRateCapMember 2016-09-30 0000798783 us-gaap:InterestRateCapMember 2013-07-01 2013-09-30 0000798783 us-gaap:InterestRateCapMember 2014-01-01 2014-03-31 0000798783 us-gaap:InterestRateCapMember 2016-04-01 2016-06-30 0000798783 us-gaap:InterestRateCapMember 2016-07-01 2016-09-30 0000798783 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:InterestRateCapMember 2013-09-30 0000798783 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:InterestRateCapMember 2014-03-31 0000798783 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:InterestRateCapMember 2016-06-30 0000798783 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:InterestRateCapMember 2016-09-30 10-Q false 2016-09-30 2016 Q3 UHT UNIVERSAL HEALTH REALTY INCOME TRUST 0000798783 --12-31 Accelerated Filer 13598144

4066000

4019000

12226000

11916000

9273000 8763000 27118000 26438000

1118000

1085000

3557000

3453000

2168000 1620000 5984000 5523000 176000 199000 603000 607000

16801000

15686000

49488000

47937000

5893000

5424000

16872000

16817000

832000

708000

2380000

2067000

4663000

4461000

13603000

13921000

331000 477000 204000

11719000

10593000

33332000

33009000

5082000

5093000

16156000

14928000

1110000

561000

3396000

1826000

8742000

-2374000

-2015000

-6783000

-6157000

3818000

3639000

12769000

19339000

0.28

0.27

0.95

1.46

0.28

0.27

0.95

1.45

13575000

13298000

13426000

13289000

4000

5000

8000

13575000

13302000

13431000

13297000

-7000

-15000

-75000

-94000

-23000

-69000

16000

8000

-6000

-25000

3834000

3647000

12763000

19314000

517726000

469933000

133929000

121161000

383797000

348772000

48615000

41724000

432412000

390496000

36765000

31597000

3982000

3894000

2256000

2116000

4649000 4292000

23014000

19757000

7311000

6351000

510389000

458503000

192250000

142150000

107660000

110156000

551000

504000

10037000

6807000

4548000 3844000

315046000

263461000

136000

133000

255466000

241700000

568055000

555286000

628214000

601983000

-100000

-94000

195343000

195042000

510389000

458503000

25800000

25100000

0.01

5000000

0.01

95000000

13598082

13327020

13598082

13327020

16920000

16884000

-166000

-169000

354000

316000

497000 311000

203000

-278000

604000 869000

-47000

75000

482000

533000

29752000

27300000

5454000

418000

634000

318000 168000 1045000

-7104000

-3667000

2000000

420000

52193000

16765000

2250000

-64219000

-19887000

50100000

24600000

2407000

7383000

307000

1000000

26231000

25494000

30000 17000

13430000

1671000

34555000

-7623000

88000

-210000

3861000

3651000

6491000

6052000

9886000

3144000

<div> (1) General This Quarterly Report on Form 10-Q is for the quarter ended September  30, 2016. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries. In this Quarterly Report on Form 10-Q, the term “revenues” does not include the revenues of the unconsolidated limited liability companies (“LLCs”) in which we have various non-controlling equity interests ranging from 33% to 95%.  As of September 30, 2016, we had investments in five jointly-owned LLCs/LPs which own medical office buildings, all of which are accounted for by the equity method (see Note 5). These LLCs are included in our financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest. The financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these financial statements be read in conjunction with the financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2015.  </div>

<div> (2) Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions Leases: We commenced operations in 1986 by purchasing properties of certain subsidiaries from UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and rental terms for each facility are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. These hospital leases with subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another. The combined revenues generated from the leases on the UHS hospital facilities accounted for approximately 23% and 25% of our consolidated revenues for the three months ended September 30, 2016 and 2015, respectively, and approximately 24% and 25% of our consolidated revenues for the nine months ended September 30, 2016 and 2015, respectively.  Including 100% of the revenues generated at the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%, the leases on the UHS hospital facilities accounted for approximately 19% and 20% of the combined consolidated and unconsolidated revenue for the three months ended September 30, 2016 and 2015, respectively, and approximately 20% of the combined consolidated and unconsolidated revenue for each of the nine months ended September 30, 2016 and 2015. In addition, we have seventeen medical office buildings (“MOBs”), including one currently under construction, or free-standing emergency departments (“FEDs”), that are either wholly or jointly-owned by us, and include or will include tenants which are subsidiaries of UHS.   Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of all hospital properties with subsidiaries of UHS, UHS has the option to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities at the end of the lease terms or any renewal terms at the appraised fair market value. In addition, the Master Lease, as amended during 2006, includes a change of control provision whereby UHS has the right, upon one month’s notice should a change of control of the Trust occur, to purchase any or all of the three leased hospital properties listed below at their appraised fair market value. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer. The leases related to the hospital facilities of UHS are guaranteed by UHS and cross-defaulted with one another. In June, 2016, three wholly-owned subsidiaries of UHS provided the required notice to us, exercising the 5-year renewal options on the leases related to our acute care hospitals noted in the table below.  The renewals extended the lease terms on these facilities, at existing lease rates, to December, 2021.  The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hospital Name</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Renewal <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">McAllen Medical Center</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,485,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wellington Regional Medical Center</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,030,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Southwest Healthcare System, Inland Valley Campus</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,648,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</td> </tr> </table></div> <p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (a)</td> <td valign="top"> UHS has two 5-year renewal options at existing lease rates (through 2031).</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (b)</td> <td valign="top"> UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).</td></tr></table></div> Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital and FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to the these leases.   During the first quarter of 2016, we committed to invest up to $21.1 million in the development and construction of the Henderson Medical Plaza, an MOB located on the campus of the Henderson Hospital Medical Center which is owned by a UHS subsidiary and opened in late October, 2016.  A ground lease has been executed between the limited liability company that owns the MOB and a subsidiary of UHS, the terms of which include a seventy-five year lease term with two ten-year renewal options at the Lessee’s option at an adjusting lease rate. We have invested $4.6 million in this MOB as of September 30, 2016. The MOB is scheduled to be completed and opened during the first quarter of 2017. Advisory Agreement: UHS of Delaware, Inc. (the “Advisor”), a wholly-owned subsidiary of UHS, serves as Advisor to us under an Advisory Agreement (the “Advisory Agreement”) dated December 24, 1986. Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory. In December of 2015, based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the Advisory agreement was renewed for 2016 pursuant to the same terms as the Advisory Agreement in place during 2015. The average real estate assets for advisory fee calculation purposes exclude certain items from our consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, base and bonus rent receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. In addition, the Advisor is entitled to an annual incentive fee equal to 20% of the amount by which cash available for distribution to shareholders for each year, as defined in the Advisory Agreement, exceeds 15% of our equity as shown on our consolidated balance sheet, determined in accordance with generally accepted accounting principles without reduction for return of capital dividends. The Advisory Agreement defines cash available for distribution to shareholders as net cash flow from operations less deductions for, among other things, amounts required to discharge our debt and liabilities and reserves for replacement and capital improvements to our properties and investments. No incentive fees were paid during the first nine months of 2016 or 2015 since the incentive fee requirements were not achieved. Advisory fees incurred and paid (or payable) to UHS amounted to $832,000 and $708,000 for the three months ended September 30, 2016 and 2015, respectively, and were based upon average invested real estate assets of $475 million and $405 million for the three-month periods ended September 30, 2016 and 2015, respectively.  Advisory fees incurred and paid (or payable) to UHS amounted to $2.4 million and $2.1 million for the nine months ended September 30, 2016 and 2015, respectively, and were based upon average invested real estate assets of $453 million and $394 million for the nine-month periods ended September 30, 2016 and 2015, respectively. Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of September 30, 2016 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses. Share Ownership: As of September 30, 2016 and December 31, 2015, UHS owned 5.8% and 5.9%, respectively, of our outstanding shares of beneficial interest. SEC reporting requirements of UHS: UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the leases on the hospital facilities leased to wholly-owned subsidiaries of UHS comprised approximately 23% and 25% of our consolidated revenues during the three month periods ended September 30, 2016 and 2015, respectively, and comprised approximately 24% and 25% of our consolidated revenues during the nine months ended September 30, 2016 and 2015, respectively, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC’s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.</div>

<div> (3) Dividends and Equity Issuance Program Dividends: We declared and paid dividends of $8.8 million, or $.65 per share, during the third quarter of 2016 and $8.5 million, or $.64 per share, during the third quarter of 2015.  We declared and paid dividends of $26.2 million, or $1.945 per share, during the nine-month period ended September 30, 2016 and $25.5 million, or $1.915 per share, during the nine-month period ended September 30, 2015. Equity Issuance Program: During the second quarter of 2016, we recommenced our at-the-market (“ATM”) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of approximately $23.3 million to or through Merrill Lynch, Pierce, Fenner and Smith, Incorporated (“Merrill Lynch”), as sales agent and/or principal. The common shares were offered pursuant to the Registration Statement filed with the Securities and Exchange Commission, which became effective during the fourth quarter of 2015. Pursuant to the ATM Program, during the first nine months of 2016, there were 249,016 shares issued at an average price of $55.30 per share (all of which were issued during the second quarter), which generated approximately $13.2 million of cash net proceeds (net of approximately $558,000, consisting of compensation of $344,000 to Merrill Lynch, as well as $214,000 of other various fees and expenses). Since inception of this ATM program, we have issued 829,916 shares at an average price of $48.77 per share, which generated approximately $38.8 million of net proceeds (net of approximately $1.7 million, consisting of compensation of $1.0 million to Merrill Lynch as well as $680,000 of other various fees and expenses).</div>

<div> (4) Acquisitions, Dispositions and New Construction Nine Months Ended September 30, 2016: Acquisition: During the nine months ended September 30, 2016, we spent $52.2 million to: <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:10%;white-space:nowrap">  </td> <td valign="top" style="width:3.33%;white-space:nowrap"> •</td> <td valign="top"> purchase the Frederick Memorial Hospital Crestwood, an MOB located in Frederick, Maryland, during the third quarter for approximately $24.3 million.  The property, which consists of approximately 62,300 rentable square feet, is fully occupied pursuant to the terms of triple-net leases with an average remaining lease term of approximately twelve years at the time of acquisition.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:10%;white-space:nowrap">  </td> <td valign="top" style="width:3.33%;white-space:nowrap"> •</td> <td valign="top"> purchase the Chandler Corporate Center III located in Chandler, Arizona, during the second quarter for approximately $18.0 million.  The property, which consists of 82,000 rentable square feet, is currently 92% occupied by one tenant pursuant to the terms of a twelve year escalating triple-net lease, with a ten year fair-market value renewal option. The lease had a remaining lease term of approximately 11.3 years at the time of acquisition.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:10%;white-space:nowrap">  </td> <td valign="top" style="width:3.33%;white-space:nowrap"> •</td> <td valign="top"> purchase the Madison Professional Office Building located in Madison, Alabama, during the first quarter for approximately $10.1 million (including $150,000 deposit made in 2015). This multi-tenant property consists of approximately 30,100 rentable square feet and is fully occupied with an average remaining lease term of approximately 6.2 years at the time of acquisition.</td></tr></table></div>   The aggregate purchase price for these acquisitions was allocated to the assets acquired and liabilities assumed consisting of tangible property and intangible assets and liabilities, based on the fair value estimated or finalized at acquisition as detailed in the table below. Final allocations of the total purchase price for allocations currently estimated will be recorded during the fourth quarter of 2016, pursuant to a third-party appraisal and will be based upon the fair value at acquisition.  While they are not expected to be materially different than those shown, any material adjustments to the estimates will be reflected, retroactively, as of the date of acquisition.  Previous reported estimated purchase price allocations that have been finalized in the third quarter did not have a material impact on our consolidated financial statements The intangible assets include the value of in-place leases at the properties at the time of acquisition as well as the above market lease values. The value of the in-place leases will be amortized over the average remaining lease terms of approximately 6 to 12 years at the time of acquisition.  The above/below market leases, which are reflected below as intangible assets/below-market intangibles will be amortized over the remaining term of the respective leases. The estimated aggregate allocation is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:432pt;;"> <tr> <td style="width:367.5pt;"></td> <td style="width:64.5pt;"></td> </tr> <tr> <td valign="top"> Land</td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6,891</td> </tr> <tr> <td valign="top"> Buildings and improvements</td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,647</td> </tr> <tr> <td valign="top"> Intangible assets</td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,094</td> </tr> <tr> <td valign="top"> Below-market intangibles</td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,289)</td> </tr> <tr> <td valign="top"> Deposit………………………………………………………………………………………..</td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    (150)</td> </tr> <tr> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top"> Net cash paid</td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$52,193</td> </tr> <tr> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="border-top:Double 2.25pt;padding-top:1pt;text-align:center;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> For these properties acquired during 2016, we recorded aggregate net revenue of approximately $723,000 and $1.1 million during the three and nine month periods ended September 30, 2016, respectively, since the date of acquisition. The aggregate net losses generated by these properties since the date of acquisition, including the cost of borrowings and advisory fee expenses was approximately $47,000 and $134,000 during the three and nine month periods ended September 30, 2016, respectively.   Assuming the 2016 acquisitions occurred on January 1, 2015, our pro forma net revenues for the three and nine months ended September 30, 2015, would have been approximately $16.4 million and $50.1 million, respectively, and our pro forma net income for the three and nine months ended September 30, 2015, would have been approximately $3.4 million, or $.25 per diluted share, and $18.7 million, or $1.40 per diluted share, respectively.  The Chandler Corporate Center III was not operational during the first nine months of 2015.  Assuming these acquisitions occurred on January 1, 2016, our pro forma net revenues for the three and nine months ended September 30, 2016, would have been approximately $17.2 million and $51.7 million, respectively, and the aggregate effect on our net income for the three and nine months ended September 30, 2016 was not material.   New Construction: During the first quarter of 2016, we committed to invest up to $21.1 million in the development and construction of the Henderson Medical Plaza, an MOB located on the campus of the Henderson Hospital Medical Center which is owned by a UHS subsidiary and opened in late October, 2016.  A ground lease has been executed between the limited liability company that owns the MOB and a subsidiary of UHS, the terms of which include a seventy-five year lease term with two ten-year renewal options at the Lessee’s option at an adjusting lease rate. We have invested $4.6 million on the development and construction for this MOB as of September 30, 2016. The MOB is scheduled to be completed and opened during the first quarter of 2017.   Dispositions:   There were no divestitures during the first nine months of 2016. Nine Months Ended September 30, 2015: Property Exchange Transaction: In May, 2015, in exchange for the real property of Sheffield Medical Building (“Sheffield”), a 73,446 square foot medical office building (“MOB”) located in Atlanta, Georgia, we received $2 million in cash and the real property of two MOBs located in Sandy Springs and Vinings, Georgia, from an unrelated third party. In connection with the two MOBs acquired in this transaction, triple net, master lease agreements applicable to 100% of the combined 36,700 rentable square feet of these properties were executed with the counterparty. These master lease agreements have initial terms of 15 years and provide for 3% annual rent increases. We recorded an $8.7 million gain which is included in our Condensed Consolidated Statements of Income for the nine-month period ended September 30, 2015, representing the difference between recorded net book value of Sheffield and the fair values of the properties exchanged, combined with the cash proceeds received. Acquisitions: In February, 2015, we purchased the Haas Medical Office Park, two single story buildings having an aggregate of approximately 16,000 rentable square feet, located in Ottumwa, Iowa, for approximately $4.1 million. In January and February of 2015, we purchased from wholly-owned subsidiaries of UHS, the real property of two newly-constructed and recently opened FEDs located in Weslaco and Mission, Texas, for an aggregate acquisition cost of approximately $12.8 million. Each FED consists of approximately 13,600 square feet and is operated by wholly-owned subsidiaries of UHS. In connection with these acquisitions, ten-year lease agreements with six 5-year renewal terms were executed with UHS for each FED. In connection with the lease agreements, the lessee shall have the option to purchase the leased property upon the expiration of the fixed term and each five-year extended term at the fair market value at that time. Dispositions:   There were no divestitures during the first nine months of 2015.  </div>

<div> (5) Summarized Financial Information of Equity Affiliates In accordance with the Financial Accounting Standards Board’s (“FASB”) standards and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting.  The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied. At September 30, 2016, we have non-controlling equity investments or commitments in five jointly-owned LLCs/LPs which own MOBs. As of September 30, 2016, we accounted for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities and we do not have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that manage and hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash fundings are typically advanced as equity or member loans. These entities maintain property insurance on the properties. <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective February 1, 2016, we purchased an additional 10% ownership interest in the Arlington Medical Properties, LLC from the third-party minority member, subject to certain agreed upon terms and conditions. Including this additional ownership interest, we currently own 85% of this LLC which is accounted for on an unconsolidated basis pursuant to the equity method. The following property table represents the five LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of September 30, 2016:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of LLC/LP</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property Owned by LLC</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suburban Properties</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">St. Matthews Medical Plaza II</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (a.)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mid Coast Hospital MOB</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arlington Medical Properties (b.)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Saint Mary’s Professional Office Building</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (c.)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (d.)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forney Medical Plaza II</td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (a.)</td> <td valign="top"> This LLC has a third-party term loan, which is non-recourse to us, of $8.7 million outstanding as of September 30, 2016.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (b.)</td> <td valign="top"> We have funded $5.2 million in equity as of September 30, 2016 and are committed to invest an additional $623,000. During the fourth quarter of 2015, we advanced this LLC a member loan, the funds of which were utilized to repay its $22.8 million outstanding third-party mortgage loan on its scheduled maturity date.  The terms of the member loan are similar to those in place pursuant to the third-party mortgage loan that was repaid. Additionally, pursuant to the terms and conditions of an agreement executed in February, 2016, we purchased an additional 10% of the ownership interest in this LLC from the existing third-party member for approximately $4.8 million in cash, thereby increasing our ownership interest to 85%. </td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (c.)</td> <td valign="top"> We have funded $2.8 million in equity as of September 30, 2016, and are committed to fund an additional $100,000. This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LLC has a third-party term loan, which is non-recourse to us, of $14.5 million outstanding as of September 30, 2016.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (d.)</td> <td valign="top"> We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of September 30, 2016. This LLC has a third-party term loan, which is non-recourse to us, of $5.3 million outstanding as of September 30, 2016.</td></tr></table></div> Below are the condensed combined statements of income (unaudited) for the LLCs accounted for under the equity method at September 30, 2016 and 2015.       <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.78%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,776</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,638</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,437</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,799</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,329</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,461</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,025</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,194</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">646</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">634</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,910</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,788</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest, net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">656</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,928</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,907</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,165</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">887</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,574</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,910</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of net income (a.)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,110</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">561</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,396</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,826</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (a.)</td> <td valign="top"> Our share of net income for the three and nine months ended September 30, 2016 includes approximately $291,000 and $880,000, respectively, of interest income earned by us on an advance made to Arlington Medical Properties, LLC (advance balance payable to us is approximately $21.8 million as of September 30, 2016). There were no advances outstanding during the first nine months of 2015, therefore there was no interest income earned by us for the three and nine months ended September 30, 2015. Also, as mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% previously. </td></tr></table></div>   Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs in which we hold noncontrolling ownership interests and that were accounted for under the equity method as of September 30, 2016 and December 31, 2015:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net property, including CIP</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,317</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,668</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,343</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,264</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,660</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,932</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,832</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,538</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mortgage notes payable, non-recourse to us</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,497</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,895</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advances payable to us</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,855</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,489</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,476</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,010</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and equity</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,660</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,932</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in and advances to LLCs reflected as:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Investments in LLCs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,910</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,108</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Advances to LLCs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,855</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,489</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in and advances to LLCs before</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   amounts included in accrued expenses and other liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,765</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,597</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Amounts included in accrued expenses and other liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,771</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,105</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in and advances to LLCs, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,994</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,492</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>     As of September 30, 2016, and December 31, 2015, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mortgage Loan Balance (a.)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of LLC/LP</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9/30/2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity Date</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,333</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,427</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August, 2017</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,496</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,670</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2021</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,668</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,798</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2024</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,497</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,895</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (a.)</td> <td valign="top"> All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.</td></tr></table></div>   Pursuant to the operating and/or partnership agreements of the five LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.  </div>

<div> (6) Recent Accounting Pronouncements   In August, 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which adds or clarifies guidance of the classification of certain cash receipts and payments in the statement of cash flows with the intent to alleviate diversity in practice for classifying various types of cash flows.  This ASU is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted.  We are currently evaluating the impact of this ASU on our statement of cash flows.   In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASU 2016-02 supersedes the previous leases standard, Leases (Topic 840). The standard is effective on January 1, 2019, with early adoption permitted. We are currently in the process of evaluating the impact the adoption of ASU 2016-02 will have on our financial position or results of operations.   In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs, an update to the accounting standard relating to the presentation of debt issuance costs. Under the new guidance, debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability. In the event that there is not an associated debt liability recorded in the consolidated financial statements, the debt issuance costs will continue to be recorded on the consolidated balance sheet as an asset until the debt liability is recorded.  The new standard became effective for the Trust on January 1, 2016. The adoption of this guidance did not have a material impact on our consolidated financial position or results of operations as the update only related to changes in financial statement presentation.     In February 2015, the FASB issued ASU No. 2015-02, Consolidation – Amendments to the Consolidation Analysis, which amends the current consolidation guidance affecting both the variable interest entity (“VIE”) and voting interest entity (“VOE”) consolidation models. The standard does not add or remove any of the characteristics in determining if an entity is a VIE or VOE, but rather enhances the way the Company assesses some of these characteristics. The new standard became effective for the Trust on January 1, 2016 and did not have a material impact on our consolidated financial position or results of operations as none of its existing consolidation conclusions were changed.   In 2014, the FASB issued ASU 2014-09, Revenue From Contracts With Customers (“ASU 2014-09”), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASU 2014-09 states that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment. In 2015, the FASB provided for a one-year deferral of the effective date for ASU 2014-09, which is now effective for us beginning January 1, 2018. We are continuing to evaluate ASU 2014-09 (and related clarifying guidance issued by the FASB); however, we do not expect its adoption to have a significant impact on our consolidated financial statements, as a substantial portion of our revenue consists of rental income from leasing arrangements, which is specifically excluded from ASU 2014-09.</div>

<div> (7) Debt and Financial Instruments Debt:   Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $250 million revolving credit facility, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances pursuant to our ATM equity issuance program.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit facility borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth. On March 27, 2015, we entered into a $185 million revolving credit agreement (“Credit Agreement”) which was amended on May 24, 2016 to, among other things, increase the borrowing capacity to $250 million. The amended Credit Agreement, which is scheduled to mature in March, 2019, includes a $40 million sub limit for letters of credit and a $20 million sub limit for swingline/short-term loans. The Credit Agreement also provides a one-time option to extend the maturity date for an additional one year period, and an option to increase the total facility borrowing capacity up to an additional $50 million, subject to lender agreement. Borrowings under the Credit Agreement are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the Credit Agreement are secured by first priority security interests in and liens on all equity interests in the Trust’s wholly-owned subsidiaries. Borrowings made pursuant to the Credit Agreement will bear interest, at our option, at one, two, three, or six month LIBOR plus an applicable margin ranging from 1.50% to 2.00% or at the Base Rate plus an applicable margin ranging from 0.50% to 1.00%. The Credit Agreement defines “Base Rate” as the greatest of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%. A commitment fee of 0.20% to 0.40% (depending on our total leverage ratio) will be charged on the average unused portion of the revolving credit commitments. The margins over LIBOR, Base Rate and the commitment fee are based upon our ratio of debt to total capital. At September 30, 2016, the applicable margin over the LIBOR rate was 1.625%, the margin over the Base Rate was 0.625%, and the commitment fee was 0.25%. At September 30, 2016, we had $192.3 million of outstanding borrowings and $2.7 million of letters of credit outstanding under our Credit Agreement. We had $55.0 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of September 30, 2016.  There are no compensating balance requirements.     The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at September 30, 2016. We also believe that we would remain in compliance if the full amount of our commitment was borrowed. The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Covenant</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible net worth</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,329</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total leverage</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">< 60%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secured leverage</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">< 30%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unencumbered leverage</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">< 60%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed charge coverage</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">> 1.50x</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7x</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   As indicated on the following table, we have fourteen mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of September 30, 2016, with a combined outstanding balance of $107.8 million, excluding net debt premium of $132,000 and net of net financing fees of $321,000 (amounts in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Facility Name</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)(a)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building III <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   floating rate mortgage loan (b.)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,462</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.77</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2016</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peace Health fixed rate mortgage loan (b.)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,434</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.64</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April, 2017</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Auburn Medical II floating rate mortgage loan (b.)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,783</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.27</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April, 2017</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical Center of Western Connecticut fixed rate <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan (b.)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,568</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2017</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building II fixed <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   rate mortgage loan (b.)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,175</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October, 2017</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phoenix Children’s East Valley Care Center fixed rate <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,239</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.88</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2017</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Centennial Hills Medical Office Building floating rate <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,116</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.77</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2018</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sparks Medical Building/Vista Medical Terrace <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   floating rate mortgage loan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,260</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.77</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February, 2018</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rosenberg Children’s Medical Plaza fixed rate <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,190</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.85</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May, 2018</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vibra Hospital-Corpus Christi fixed rate mortgage loan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,746</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.50</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July, 2019</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700 Shadow Lane and Goldring MOBs fixed rate <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,294</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.54</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2022</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRB Medical Office Building fixed rate mortgage loan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,362</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2022</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Desert Valley Medical Center fixed rate mortgage loan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,114</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.62</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2023</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuscan Professional Building fixed rate mortgage loan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,106</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.56</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.66%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2025</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.78%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,849</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.66%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.66%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (a.)</td> <td valign="top"> All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (b.)</td> <td valign="top"> This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our Credit Agreement. </td></tr></table></div> The mortgages are secured by the real property of the buildings as well as property leases and rents. The mortgages have a combined fair value of approximately $110 million as of September 30, 2016. Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow. At December 31, 2015, we had fourteen mortgages, all of which were non-recourse to us, included in our consolidated balance sheet. The combined outstanding balance of these fourteen mortgages was $110.3 million (excluding net debt premium of $298,000 and net of net financing fees of $398,000), and had a combined fair value of approximately $112 million. Financial Instruments: During the third quarter of 2013, we entered into an interest rate cap on a total notional amount of $10 million whereby we paid a premium of $136,000. During the first quarter of 2014, we entered into two additional interest rate cap agreements on a total notional amount of $20 million whereby we paid premiums of $134,500. In exchange for the premium payments, the counterparties agreed to pay us the difference between 1.50% and one-month LIBOR if one-month LIBOR rises above 1.50% during the term of the cap. From inception through September 30, 2016, no payments have been made to us by the counterparties pursuant to the terms of these caps which expire in January, 2017.   During the second quarter of 2016, we entered into an interest rate cap on the total notional amount of $30 million whereby we paid a premium of $115,000.  In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.50% and one-month LIBOR if one-month LIBOR rises above 1.50% during the term of the cap.  This interest rate cap becomes effective in January, 2017, coinciding with the expiration of the above-mentioned interest rate caps and expires in March, 2019.  During the third quarter of 2016, we entered into an additional interest rate cap agreement on a total notional amount of $30 million whereby we paid a premium of $55,000.  In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.5% and one-month LIBOR if one-month LIBOR rises above 1.5% during the term of the cap.  This interest rate cap became effective in October, 2016 and expires in March, 2019.</div>

<div> (8) Segment Reporting Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio. Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.  </div>

<div> The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hospital Name</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Renewal <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">McAllen Medical Center</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,485,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wellington Regional Medical Center</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,030,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Southwest Healthcare System, Inland Valley Campus</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,648,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</td> </tr> </table></div> <p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (a)</td> <td valign="top"> UHS has two 5-year renewal options at existing lease rates (through 2031).</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (b)</td> <td valign="top"> UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).</td></tr></table></div></div>

<div> The estimated aggregate allocation is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:432pt;;"> <tr> <td style="width:367.5pt;"></td> <td style="width:64.5pt;"></td> </tr> <tr> <td valign="top"> Land</td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$6,891</td> </tr> <tr> <td valign="top"> Buildings and improvements</td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,647</td> </tr> <tr> <td valign="top"> Intangible assets</td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,094</td> </tr> <tr> <td valign="top"> Below-market intangibles</td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,289)</td> </tr> <tr> <td valign="top"> Deposit………………………………………………………………………………………..</td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    (150)</td> </tr> <tr> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top"> Net cash paid</td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$52,193</td> </tr> <tr> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;"> <p style="border-top:Double 2.25pt;padding-top:1pt;text-align:center;margin-top:1pt;line-height:1pt;margin-bottom:0pt;margin-left:14.4pt;;margin-right:1.85%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following property table represents the five LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of September 30, 2016:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of LLC/LP</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property Owned by LLC</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suburban Properties</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">St. Matthews Medical Plaza II</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (a.)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mid Coast Hospital MOB</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arlington Medical Properties (b.)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Saint Mary’s Professional Office Building</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (c.)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (d.)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forney Medical Plaza II</td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (a.)</td> <td valign="top"> This LLC has a third-party term loan, which is non-recourse to us, of $8.7 million outstanding as of September 30, 2016.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (b.)</td> <td valign="top"> We have funded $5.2 million in equity as of September 30, 2016 and are committed to invest an additional $623,000. During the fourth quarter of 2015, we advanced this LLC a member loan, the funds of which were utilized to repay its $22.8 million outstanding third-party mortgage loan on its scheduled maturity date.  The terms of the member loan are similar to those in place pursuant to the third-party mortgage loan that was repaid. Additionally, pursuant to the terms and conditions of an agreement executed in February, 2016, we purchased an additional 10% of the ownership interest in this LLC from the existing third-party member for approximately $4.8 million in cash, thereby increasing our ownership interest to 85%. </td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (c.)</td> <td valign="top"> We have funded $2.8 million in equity as of September 30, 2016, and are committed to fund an additional $100,000. This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LLC has a third-party term loan, which is non-recourse to us, of $14.5 million outstanding as of September 30, 2016.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (d.)</td> <td valign="top"> We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of September 30, 2016. This LLC has a third-party term loan, which is non-recourse to us, of $5.3 million outstanding as of September 30, 2016.</td></tr></table></div></div>

<div> Below are the condensed combined statements of income (unaudited) for the LLCs accounted for under the equity method at September 30, 2016 and 2015.       <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.78%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,776</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,638</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,437</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,799</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,329</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,461</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,025</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,194</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">646</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">634</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,910</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,788</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest, net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">656</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,928</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,907</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,165</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">887</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,574</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,910</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of net income (a.)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,110</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">561</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,396</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,826</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (a.)</td> <td valign="top"> Our share of net income for the three and nine months ended September 30, 2016 includes approximately $291,000 and $880,000, respectively, of interest income earned by us on an advance made to Arlington Medical Properties, LLC (advance balance payable to us is approximately $21.8 million as of September 30, 2016). There were no advances outstanding during the first nine months of 2015, therefore there was no interest income earned by us for the three and nine months ended September 30, 2015. Also, as mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% previously. </td></tr></table></div>  </div> <div> Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs in which we hold noncontrolling ownership interests and that were accounted for under the equity method as of September 30, 2016 and December 31, 2015:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net property, including CIP</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,317</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,668</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,343</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,264</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,660</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,932</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,832</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,538</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mortgage notes payable, non-recourse to us</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,497</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,895</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advances payable to us</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,855</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,489</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,476</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,010</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and equity</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,660</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,932</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in and advances to LLCs reflected as:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Investments in LLCs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,910</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,108</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Advances to LLCs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,855</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,489</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in and advances to LLCs before</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   amounts included in accrued expenses and other liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,765</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,597</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Amounts included in accrued expenses and other liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,771</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,105</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in and advances to LLCs, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,994</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,492</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>    </div>

<div> As of September 30, 2016, and December 31, 2015, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mortgage Loan Balance (a.)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of LLC/LP</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9/30/2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity Date</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,333</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,427</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August, 2017</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,496</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,670</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2021</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,668</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,798</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2024</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,497</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,895</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (a.)</td> <td valign="top"> All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.</td></tr></table></div></div>

<div> The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Covenant</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible net worth</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,329</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total leverage</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">< 60%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secured leverage</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">< 30%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unencumbered leverage</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">< 60%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed charge coverage</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">> 1.50x</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7x</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Facility Name</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)(a)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building III <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   floating rate mortgage loan (b.)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,462</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.77</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2016</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peace Health fixed rate mortgage loan (b.)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,434</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.64</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April, 2017</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Auburn Medical II floating rate mortgage loan (b.)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,783</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.27</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April, 2017</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical Center of Western Connecticut fixed rate <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan (b.)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,568</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2017</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building II fixed <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   rate mortgage loan (b.)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,175</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October, 2017</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phoenix Children’s East Valley Care Center fixed rate <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,239</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.88</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2017</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Centennial Hills Medical Office Building floating rate <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,116</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.77</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2018</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sparks Medical Building/Vista Medical Terrace <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   floating rate mortgage loan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,260</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.77</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February, 2018</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rosenberg Children’s Medical Plaza fixed rate <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,190</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.85</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May, 2018</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vibra Hospital-Corpus Christi fixed rate mortgage loan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,746</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.50</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July, 2019</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700 Shadow Lane and Goldring MOBs fixed rate <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,294</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.54</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2022</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRB Medical Office Building fixed rate mortgage loan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,362</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2022</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Desert Valley Medical Center fixed rate mortgage loan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,114</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.62</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2023</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuscan Professional Building fixed rate mortgage loan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,106</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.66%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.56</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.66%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2025</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.78%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,849</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.66%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.66%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (a.)</td> <td valign="top"> All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> (b.)</td> <td valign="top"> This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our Credit Agreement. </td></tr></table></div></div>

0.33

0.95

P13Y P15Y 6 P5Y

0.23

0.25

0.24

0.25

0.19

0.20

17 1 P90D P180D P180D 3 2021-12 3 5485000 3030000 2648000 2021-12 2021-12 2021-12 P10Y P10Y P10Y 2 P5Y 2031 2 P5Y 2022 2031 21100000 P75Y 2 P10Y

4600000

0.20 0.15

832000

708000

2400000

2100000

475000000 405000000 453000000 394000000 0.058 0.059

8800000

8500000

0.65

0.64

1.945

1.915

23300000

249016

829916

249016

55.30 48.77 55.30

13200000

38800000

558000

1700000

344000 1000000 214000 680000

52200000

24300000

62300

P12Y

18000000

82000

P11Y3M18D

0.92 P12Y

P10Y

10100000

150000

30100

P6Y2M12D

P6Y

P12Y

6891000

39647000

7094000

1289000 150000

52193000

723000

1100000

47000

134000

16400000

50100000

17200000

51700000

3400000

18700000

0.25

1.40

73446

2000000

2 1.00

36700

P15Y

0.03

8700000

16000

4100000

12800000

13600

P10Y P5Y

0.33

0.95

0.10

0.85

0.33

0.74

0.85

0.95

St. Matthews Medical Plaza II Mid Coast Hospital MOB Saint Mary’s Professional Office Building Texoma Medical Plaza Forney Medical Plaza II

8700000

5200000 623000

22800000

0.10

4800000 0.85 2800000 100000

14500000

2100000 2500000

5300000

3776000

3638000

11437000

10799000

1329000 1461000 4025000 4194000 646000 634000 1910000 1788000 636000 656000 1928000 1907000

1165000

887000

3574000

2910000

291000

880000

21800000 0.75 0.85 61317000 61668000 5343000 5264000

66660000

66932000

2832000

2538000

28497000 28895000 21855000 22489000

13476000

13010000

66660000

66932000

14910000 9108000 21855000 22489000 1771000 1105000

34994000

30492000

5333000 14496000 8668000 28497000 5427000 14670000 8798000 28895000 2017-08 2021-09 2024-12 P60D P90D

185000000

250000000

2019-03

40000000

20000000

50000000

One, two, three, or six month LIBOR plus an applicable margin ranging from 1.50% to 2.00% or at the Base Rate plus an applicable margin ranging from 0.50% to 1.00%.

0.0150

0.01

0.0200

0.0050

0.0100

The greatest of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%.

0.0050

0.0020

0.0040

0.01625

0.00625

0.0025

2700000

55000000

125000000 0.60 0.30 0.60 0.0150 172329000 0.478 0.176 0.487 0.037 14

107849000

132000000

321000000

10462000

20434000

6783000

4568000

11175000

6239000

10116000

4260000

8190000

2746000

6294000

6362000

5114000

5106000

0.0377

0.0564

0.0327

0.0600

0.0550

0.0588

0.0377

0.0485

0.0650

0.0454

0.0427

0.0362

0.0556

2016-12 2017-04 2017-04 2017-06 2017-10 2017-12 2018-01 2018-02 2018-05 2019-07 2022-06 2022-12 2023-01 2025-06

110000000

110300000

298000

112000000

398000

10000000 20000000 30000000 30000000 136000 134500 115000 55000

2017-01-31

2019-03-31

0.0150

0.015

UHS has two 5-year renewal options at existing lease rates (through 2031). UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031). This LLC has a third-party term loan, which is non-recourse to us, of $8.7 million outstanding as of September 30, 2016. We have funded $5.2 million in equity as of September 30, 2016 and are committed to invest an additional $623,000. During the fourth quarter of 2015, we advanced this LLC a member loan, the funds of which were utilized to repay its $22.8 million outstanding third-party mortgage loan on its scheduled maturity date. The terms of the member loan are similar to those in place pursuant to the third-party mortgage loan that was repaid. Additionally, pursuant to the terms and conditions of an agreement executed in February, 2016, we purchased an additional 10% of the ownership interest in this LLC from the existing third-party member for approximately $4.8 million in cash, thereby increasing our ownership interest to 85%. We have funded $2.8 million in equity as of September 30, 2016, and are committed to fund an additional $100,000. This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LLC has a third-party term loan, which is non-recourse to us, of $14.5 million outstanding as of September 30, 2016. We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of September 30, 2016. This LLC has a third-party term loan, which is non-recourse to us, of $5.3 million outstanding as of September 30, 2016. Our share of net income for the three and nine months ended September 30, 2016 includes approximately $291,000 and $880,000, respectively, of interest income earned by us on an advance made to Arlington Medical Properties, LLC (advance balance payable to us is approximately $21.8 million as of September 30, 2016). There were no advances outstanding during the first nine months of 2015, therefore there was no interest income earned by us for the three and nine months ended September 30, 2015. Also, as mentioned above, effective February 1, 2016, we purchased an additional 10% of the ownership interest in Arlington Medical Properties, LLC thereby increasing our ownership interest to 85%, from 75% previously. All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our Credit Agreement.

EX-101.SCH 7 uht-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Statements of Income link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Statements of Comprehensive Income link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statement of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - General link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Dividends and Equity Issuance Program link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Acquisitions, Dispositions and New Construction link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Summarized Financial Information of Equity Affiliates link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Debt and Financial Instruments link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Segment Reporting link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Acquisitions, Dispositions and New Construction (Tables) link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Debt and Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - General - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Dividends and Equity Issuance Program - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Acquisitions, Dispositions and New Construction - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Allocation of Purchase Price to Assets Acquired and Liabilities Assumed (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Debt and Financial Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Segment Reporting - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 uht-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 uht-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 uht-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document - Document and Entity Information [Abstract] Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding The total amount of lease revenues recognized for the period for which the lessee was obligated under leasing arrangements regardless of any other events or conditions. This amount excludes contingent revenue and sublease revenue. In accordance with the provisions of their lease agreement, this element represents allowable charges due a landlord from its tenant. In retail stores and office leases, for example, tenant reimbursements may cover items such as taxes, utilities, and common area expenses. In accordance with the provisions of their lease agreements, this element represents allowable charges due a landlord from its tenant. In retail stores and office leases, for example, tenant reimbursements may cover items such as taxes, utilities, and common area expenses. Transaction costs. Income Statement [Abstract] Revenues: Revenues [Abstract] Base rental - UHS facilities Operating Leases Income Statement Minimum Lease Revenue Base rental - Non-related parties Base Rental Non Related Parties Bonus rental - UHS facilities Percentage Rent Tenant reimbursements and other - Non-related parties Tenant Reimbursements And Other Non Related Parties Tenant reimbursements and other - UHS facilities Tenant Reimbursements And Other Facilities Revenues, Total Revenues Expenses: Costs And Expenses [Abstract] Depreciation and amortization Depreciation And Amortization Advisory fees to UHS Owned Property Management Costs Other operating expenses Other Cost And Expense Operating Transaction costs Transaction Costs Costs and Expenses, Total Costs And Expenses Income before equity in income of unconsolidated limited liability companies ("LLCs"), interest expense and gain Operating Income Loss Equity in income of unconsolidated LLCs Income Loss From Equity Method Investments Gain on property exchange Gain Loss On Sale Of Property Plant Equipment Interest expense, net Interest Income Expense Net Net income Net Income Loss Basic earnings per share Earnings Per Share Basic Diluted earnings per share Earnings Per Share Diluted Weighted average number of shares outstanding - Basic Weighted Average Number Of Shares Outstanding Basic Weighted average number of share equivalents Weighted Average Number Diluted Shares Outstanding Adjustment Weighted average number of shares and equivalents outstanding - Diluted Weighted Average Number Of Diluted Shares Outstanding Statement Of Income And Comprehensive Income [Abstract] Net income Other comprehensive income/(loss): Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract] Unrealized losses on interest rate caps Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax Amortization of interest rate cap fees Other Comprehensive Income Loss Reclassification Adjustment From A O C I On Derivatives Net Of Tax Total other comprehensive income/(loss): Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Total comprehensive income Comprehensive Income Net Of Tax The cumulative difference between the rental payments required by a lease agreement and the rental income or expenses recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property, by the lessor or lessee, respectively. Such receivable is reduced by allowances attributable to, for instance, credit risk associated with a lessee. Amount at the balance sheet date that has been received by the entity that represents collections of cash or other assets related to real estate operations revenue for which revenue has not yet been recognized and money paid in advance to protect the provider of a product or services, such as a lessor, against damage or non-payment by the tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property and other contractual breaches. Statement Of Financial Position [Abstract] Assets: Assets [Abstract] Real Estate Investments: Real Estate Investments [Abstract] Buildings and improvements and construction in progress Real Estate Investment Property At Cost Accumulated depreciation Real Estate Investment Property Accumulated Depreciation Real Estate Investment Property, Net, Total Real Estate Investment Property Net Land Land Net Real Estate Investments Real Estate Investments Investments in and advances to limited liability companies ("LLCs") Investments In And Advances To Affiliates At Fair Value Other Assets: Other Assets [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Base and bonus rent receivable from UHS Deferred Rent Receivables Net Rent receivable - other Rent Receivable Other Intangible assets (net of accumulated amortization of $25.8 million and $25.1 million at September 30, 2016 and December 31, 2015, respectively) Intangible Assets Net Excluding Goodwill Deferred charges and other assets, net Deferred Costs And Other Assets Total Assets Assets Liabilities: Liabilities [Abstract] Line of credit borrowings Line Of Credit Mortgage notes payable, non-recourse to us, net Secured Debt Accrued interest Interest Payable Current And Noncurrent Accrued expenses and other liabilities Accrued Liabilities And Other Liabilities Tenant reserves, deposits and prepaid rents Tenant Reserves Deposits And Prepaid Rents Total Liabilities Liabilities Equity: Stockholders Equity [Abstract] Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized; none issued and outstanding Preferred Stock Value Common shares, $.01 par value; 95,000,000 shares authorized; issued and outstanding: 2016 - 13,598,082; 2015 - 13,327,020 Common Stock Value Capital in excess of par value Additional Paid In Capital Common Stock Cumulative net income Retained Earnings Accumulated Deficit Cumulative dividends Cumulative Dividends Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Total Equity Stockholders Equity Total Liabilities and Equity Liabilities And Stockholders Equity Intangible assets, accumulated amortization Finite Lived Intangible Assets Accumulated Amortization Preferred shares of beneficial interest, par value Preferred Stock Par Or Stated Value Per Share Preferred shares of beneficial interest, shares authorized Preferred Stock Shares Authorized Preferred shares of beneficial interest, issued Preferred Stock Shares Issued Preferred shares of beneficial interest, outstanding Preferred Stock Shares Outstanding Common shares, par value Common Stock Par Or Stated Value Per Share Common shares, shares authorized Common Stock Shares Authorized Common shares, issued Common Stock Shares Issued Common shares, outstanding Common Stock Shares Outstanding Increase decrease in rent receivable. Increase (decrease) in tenant reserves, deposits and prepaid rents. Equity investment distribution. Equity investments distribution. Partial settlement of dividends equivalent rights. Noncash obligation for property plant and equipment. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation Depletion And Amortization Amortization of debt premium Amortization Of Debt Discount Premium Stock-based compensation expense Share Based Compensation Gain on property exchange Changes in assets and liabilities: Increase Decrease In Operating Capital [Abstract] Rent receivable Increase Decrease In Rent Receivable Accrued expenses and other liabilities Increase Decrease In Accrued Liabilities And Other Operating Liabilities Tenant reserves, deposits and prepaid rents Increase Decrease In Tenant Reserves Deposits And Prepaid Rents Accrued interest Increase Decrease In Accrued Interest Receivable Net Other, net Increase Decrease In Other Operating Capital Net Net cash provided by operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash flows from investing activities: Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Investments in LLCs Payments To Acquire Investments Repayments of advances made to LLC Proceeds From Collection Of Advance To Affiliate Cash distributions in excess of income from LLCs Cash Distributions In Excess Of Income From Limited Liability Companies Cash distribution of refinancing proceeds from LLCs Cash Distributions Of Refinancing Proceeds From Limited Liability Companies Additions to real estate investments, net Real Estate Period Increase Decrease Cash received for property exchange Proceeds From Sale Of Property Plant And Equipment Deposit on real estate assets Payments For Proceeds From Deposits On Real Estate Acquisitions Net cash paid for acquisition of properties Payments To Acquire Property Plant And Equipment Cash paid to acquire minority interests in majority-owned LLCs Payments To Acquire Additional Interest In Subsidiaries Net cash used in investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Cash flows from financing activities: Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Net borrowings on line of credit Proceeds From Long Term Lines Of Credit Repayments of mortgages and other notes payable Repayments Of Secured Debt Financing costs paid Payments Of Financing Costs Dividends paid Payments Of Dividends Partial settlement of dividend equivalent rights Partial Settlement Of Dividends Equivalent Rights Issuance of shares of beneficial interest, net Proceeds From Issuance Or Sale Of Equity Net cash provided by (used in) financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Increase/(decrease) in cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid Net Property Exchange Transaction: Noncash Or Part Noncash Acquisition Value Of Assets Acquired [Abstract] Net assets acquired in property exchange Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 Net assets relinquished in property exchange Non Cash Obligation For Property Plant And Equipment Organization Consolidation And Presentation Of Financial Statements [Abstract] General Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Related Party Transactions [Abstract] Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Related Party Transactions Disclosure [Text Block] Equity [Abstract] Dividends and Equity Issuance Program Stockholders Equity Note Disclosure [Text Block] Business Combinations [Abstract] Acquisitions, Dispositions and New Construction Mergers Acquisitions And Dispositions Disclosures [Text Block] Equity Method Investments And Joint Ventures [Abstract] Summarized Financial Information of Equity Affiliates Equity Method Investments Disclosure [Text Block] New Accounting Pronouncements And Changes In Accounting Principles [Abstract] Recent Accounting Pronouncements New Accounting Pronouncements And Changes In Accounting Principles [Text Block] Debt and financial instruments disclosure. Debt Disclosure [Abstract] Debt and Financial Instruments Debt And Financial Instruments Disclosure [Text Block] Segment Reporting [Abstract] Segment Reporting Segment Reporting Disclosure [Text Block] Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities Schedule Of Property Subject To Or Available For Operating Lease [Text Block] Allocation of Purchase Price to Assets Acquired and Liabilities Assumed Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed Table [Text Block] Limited Liability Companies Accounted for Under Equity Method Equity Method Investments [Text Block] Equity Method Investments Summarized Income Statement Information. Condensed Combined Statements of Income (Unaudited) for Limited Liability Companies Accounted for Under Equity Method Equity Method Investments Summarized Income Statement Information Table [Text Block] Equity Method Investments Summarized Combined Balance Sheet Information. Condensed Combined Balance Sheets (Unaudited) for LLCs Accounted for Under Equity Method Equity Method Investments Summarized Combined Balance Sheet Information Table [Text Block] Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's Accounted Under Equity Method Contractual Obligation Fiscal Year Maturity Schedule Table [Text Block] Schedule of Financial Covenants. Summary of Required Compliance Ratios Giving Effect to New Covenants in Credit Agreement Schedule Of Financial Covenants Table [Text Block] Outstanding Mortgages, Excluding Net Debt Premium Schedule Of Debt Instruments [Text Block] Organization consolidation and presentation of financial statements. Organization consolidation and presentation of financial statements. Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Real Estate Property Ownership Real Estate Properties [Axis] Real Estate Properties Real Estate Properties [Domain] Medical office buildings. Medical office buildings Medical Office Buildings [Member] Investment, Name Schedule Of Equity Method Investment Equity Method Investee Name [Axis] Investment, Name Equity Method Investee Name [Domain] Unconsolidated limited liabilities. 5 Unconsolidated Limited Liability Companies Unconsolidated Limited Liabilities [Member] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Limited liability company or limited partner. Limited Liability Companies Limited Liability Company Or Limited Partner [Member] Range Range [Axis] Range Range [Member] Minimum Minimum [Member] Maximum Maximum [Member] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Non-controlling equity interest, ownership percentage Equity Method Investment Ownership Percentage Number of real estate investments Number Of Real Estate Properties Initial lease expiration period. Number of renewal options. Renewal option terms additional period. Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Related-Party Principal Tenant Universal Health Services, Inc Universal Health Services Inc [Member] Concentration Risk Type Concentration Risk By Type [Axis] Concentration Risk Type Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Revenue. Revenues Revenue [Member] Unconsolidated and Consolidated Revenue Combined consolidated and unconsolidated revenue Combined [Member] Name of Property Real Estate And Accumulated Depreciation Description Of Property [Axis] Name of Property Real Estate And Accumulated Depreciation Name Of Property [Domain] Henderson medical plaza member. Henderson Medical Plaza Henderson Medical Plaza [Member] Wholly-owned subsidiary of Universal Health Services, Inc.; Advisor to UHT Universal Health Services of Delaware Inc Universal Health Services Of Delaware Inc [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Initial lease terms Initial Lease Expiration Period Number of term renewal options Number Of Renewal Options Additional renewal terms Renewal Option Terms Additional Period Number of leased properties for medical office buildings and free standing emergency departments. Number of leased properties under construction for medical office buildings . Percentage of revenues generated from leases Concentration Risk Percentage1 Number of medical office buildings and free standing emergency departments Number Of Leased Properties For Medical Office Buildings And Free Standing Emergency Departments Number of medical office buildings under construction Number Of Leased Properties Under Construction For Medical Office Buildings Lease renewal, notice period. Period to purchase respective leased facilities after lease terms. Renewal option terms maximum additional period. Option to renew lease, notice period prior to termination date of current term Lease Renewal Notice Period Period to purchase respective leased facilities at same price after lease terms Period To Purchase Respective Leased Facilities After Lease Terms Renewal period of respective leased facilities at same price after lease terms Renewal Option Terms Maximum Additional Period Number of wholly-owned subsidiaries that provided notice. Lease expiration, month and year. Operating leases, number of renewal options at existing lease rates. Number of wholly-owned subsidiaries Number Of Wholly Owned Subsidiaries That Provided Notice Extended lease terms at existing lease rates Lease Expiration Month And Year Number of renewal options at existing lease rates Operating Leases Number Of Renewal Options At Existing Lease Rates Operating leases, annual future minimum payments receivable. Schedule Of Operating Leased Assets [Table] Schedule Of Operating Leased Assets [Table] Major Property Class Major Property Class [Axis] EX-101.PRE 11 uht-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Oct. 31, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Trading Symbol	UHT
Entity Registrant Name	UNIVERSAL HEALTH REALTY INCOME TRUST
Entity Central Index Key	0000798783
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		13,598,144

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Revenues:

Base rental - UHS facilities

$ 4,066

$ 4,019

$ 12,226

$ 11,916

Base rental - Non-related parties

9,273

8,763

27,118

26,438

Bonus rental - UHS facilities

1,118

1,085

3,557

3,453

Tenant reimbursements and other - Non-related parties

2,168

1,620

5,984

5,523

Tenant reimbursements and other - UHS facilities

176

199

603

607

Revenues, Total

16,801

15,686

49,488

47,937

Expenses:

Depreciation and amortization

5,893

5,424

16,872

16,817

Advisory fees to UHS

832

708

2,380

2,067

Other operating expenses

4,663

4,461

13,603

13,921

Transaction costs

331

477

204

Costs and Expenses, Total

11,719

10,593

33,332

33,009

Income before equity in income of unconsolidated limited liability companies ("LLCs"), interest expense and gain

5,082

5,093

16,156

14,928

Equity in income of unconsolidated LLCs

^[1]

1,110

561

3,396

1,826

Gain on property exchange

8,742

Interest expense, net

(2,374)

(2,015)

(6,783)

(6,157)

Net income

$ 3,818

$ 3,639

$ 12,769

$ 19,339

Basic earnings per share

$ 0.28

$ 0.27

$ 0.95

$ 1.46

Diluted earnings per share

$ 0.28

$ 0.27

$ 0.95

$ 1.45

Weighted average number of shares outstanding - Basic

13,575

13,298

13,426

13,289

Weighted average number of share equivalents

Weighted average number of shares and equivalents outstanding - Diluted

13,575

13,302

13,431

13,297

[1]

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 3,818	$ 3,639	$ 12,769	$ 19,339
Other comprehensive income/(loss):
Unrealized losses on interest rate caps	(7)	(15)	(75)	(94)
Amortization of interest rate cap fees	23	23	69	69
Total other comprehensive income/(loss):	16	8	(6)	(25)
Total comprehensive income	$ 3,834	$ 3,647	$ 12,763	$ 19,314

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Real Estate Investments:
Buildings and improvements and construction in progress	$ 517,726	$ 469,933
Accumulated depreciation	(133,929)	(121,161)
Real Estate Investment Property, Net, Total	383,797	348,772
Land	48,615	41,724
Net Real Estate Investments	432,412	390,496
Investments in and advances to limited liability companies ("LLCs")	36,765	31,597
Other Assets:
Cash and cash equivalents	3,982	3,894
Base and bonus rent receivable from UHS	2,256	2,116
Rent receivable - other	4,649	4,292
Intangible assets (net of accumulated amortization of $25.8 million and $25.1 million at September 30, 2016 and December 31, 2015, respectively)	23,014	19,757
Deferred charges and other assets, net	7,311	6,351
Total Assets	510,389	458,503
Liabilities:
Line of credit borrowings	192,250	142,150
Mortgage notes payable, non-recourse to us, net	107,660	110,156
Accrued interest	551	504
Accrued expenses and other liabilities	10,037	6,807
Tenant reserves, deposits and prepaid rents	4,548	3,844
Total Liabilities	315,046	263,461
Equity:
Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized; none issued and outstanding
Common shares, $.01 par value; 95,000,000 shares authorized; issued and outstanding: 2016 - 13,598,082; 2015 - 13,327,020	136	133
Capital in excess of par value	255,466	241,700
Cumulative net income	568,055	555,286
Cumulative dividends	(628,214)	(601,983)
Accumulated other comprehensive loss	(100)	(94)
Total Equity	195,343	195,042
Total Liabilities and Equity	$ 510,389	$ 458,503

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Intangible assets, accumulated amortization	$ 25.8	$ 25.1
Preferred shares of beneficial interest, par value	$ 0.01	$ 0.01
Preferred shares of beneficial interest, shares authorized	5,000,000	5,000,000
Preferred shares of beneficial interest, issued	0	0
Preferred shares of beneficial interest, outstanding	0	0
Common shares, par value	$ 0.01	$ 0.01
Common shares, shares authorized	95,000,000	95,000,000
Common shares, issued	13,598,082	13,327,020
Common shares, outstanding	13,598,082	13,327,020

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net income	$ 12,769,000	$ 19,339,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	16,920,000	16,884,000
Amortization of debt premium	(166,000)	(169,000)
Stock-based compensation expense	354,000	316,000
Gain on property exchange		(8,742,000)
Changes in assets and liabilities:
Rent receivable	(497,000)	(311,000)
Accrued expenses and other liabilities	203,000	(278,000)
Tenant reserves, deposits and prepaid rents	604,000	869,000
Accrued interest	47,000	(75,000)
Other, net	(482,000)	(533,000)
Net cash provided by operating activities	29,752,000	27,300,000
Cash flows from investing activities:
Investments in LLCs	(5,454,000)	(418,000)
Repayments of advances made to LLC	634,000
Cash distributions in excess of income from LLCs	318,000	168,000
Cash distribution of refinancing proceeds from LLCs		1,045,000
Additions to real estate investments, net	(7,104,000)	(3,667,000)
Cash received for property exchange	0	2,000,000
Deposit on real estate assets	(420,000)
Net cash paid for acquisition of properties	(52,193,000)	(16,765,000)
Cash paid to acquire minority interests in majority-owned LLCs		(2,250,000)
Net cash used in investing activities	(64,219,000)	(19,887,000)
Cash flows from financing activities:
Net borrowings on line of credit	50,100,000	24,600,000
Repayments of mortgages and other notes payable	(2,407,000)	(7,383,000)
Financing costs paid	(307,000)	(1,000,000)
Dividends paid	(26,231,000)	(25,494,000)
Partial settlement of dividend equivalent rights	(30,000)	(17,000)
Issuance of shares of beneficial interest, net	13,430,000	1,671,000
Net cash provided by (used in) financing activities	34,555,000	(7,623,000)
Increase/(decrease) in cash and cash equivalents	88,000	(210,000)
Cash and cash equivalents, beginning of period	3,894,000	3,861,000
Cash and cash equivalents, end of period	3,982,000	3,651,000
Supplemental disclosures of cash flow information:
Interest paid	$ 6,491,000	6,052,000
Property Exchange Transaction:
Net assets acquired in property exchange		9,886,000
Net assets relinquished in property exchange		$ (3,144,000)

XML 18 R7.htm IDEA: XBRL DOCUMENT

General	9 Months Ended
General	Sep. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
General	(1) General This Quarterly Report on Form 10-Q is for the quarter ended September 30, 2016. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries. In this Quarterly Report on Form 10-Q, the term “revenues” does not include the revenues of the unconsolidated limited liability companies (“LLCs”) in which we have various non-controlling equity interests ranging from 33% to 95%. As of September 30, 2016, we had investments in five jointly-owned LLCs/LPs which own medical office buildings, all of which are accounted for by the equity method (see Note 5). These LLCs are included in our financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest. The financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these financial statements be read in conjunction with the financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2015.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions

9 Months Ended

Sep. 30, 2016

Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions

(2) Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions

In June, 2016, three wholly-owned subsidiaries of UHS provided the required notice to us, exercising the 5-year renewal options on the leases related to our acute care hospitals noted in the table below. The renewals extended the lease terms on these facilities, at existing lease rates, to December, 2021. The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:

Hospital Name	Annual Minimum Rent		End of Lease Term	Renewal Term (years)
McAllen Medical Center	$	5,485,000	December, 2021		10	(a)
Wellington Regional Medical Center	$	3,030,000	December, 2021		10	(b)
Southwest Healthcare System, Inland Valley Campus	$	2,648,000	December, 2021		10	(b)

(a)	UHS has two 5-year renewal options at existing lease rates (through 2031).

(b)	UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).

Share Ownership: As of September 30, 2016 and December 31, 2015, UHS owned 5.8% and 5.9%, respectively, of our outstanding shares of beneficial interest.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Dividends and Equity Issuance Program	9 Months Ended
Dividends and Equity Issuance Program	Sep. 30, 2016
Equity [Abstract]
Dividends and Equity Issuance Program	(3) Dividends and Equity Issuance Program Dividends: We declared and paid dividends of $8.8 million, or $.65 per share, during the third quarter of 2016 and $8.5 million, or $.64 per share, during the third quarter of 2015. We declared and paid dividends of $26.2 million, or $1.945 per share, during the nine-month period ended September 30, 2016 and $25.5 million, or $1.915 per share, during the nine-month period ended September 30, 2015. Equity Issuance Program: During the second quarter of 2016, we recommenced our at-the-market (“ATM”) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of approximately $23.3 million to or through Merrill Lynch, Pierce, Fenner and Smith, Incorporated (“Merrill Lynch”), as sales agent and/or principal. The common shares were offered pursuant to the Registration Statement filed with the Securities and Exchange Commission, which became effective during the fourth quarter of 2015. Pursuant to the ATM Program, during the first nine months of 2016, there were 249,016 shares issued at an average price of $55.30 per share (all of which were issued during the second quarter), which generated approximately $13.2 million of cash net proceeds (net of approximately $558,000, consisting of compensation of $344,000 to Merrill Lynch, as well as $214,000 of other various fees and expenses). Since inception of this ATM program, we have issued 829,916 shares at an average price of $48.77 per share, which generated approximately $38.8 million of net proceeds (net of approximately $1.7 million, consisting of compensation of $1.0 million to Merrill Lynch as well as $680,000 of other various fees and expenses).

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

Acquisitions, Dispositions and New Construction

9 Months Ended

Sep. 30, 2016

Business Combinations [Abstract]

Acquisitions, Dispositions and New Construction

(4) Acquisitions, Dispositions and New Construction

Nine Months Ended September 30, 2016:

Acquisition:

During the nine months ended September 30, 2016, we spent $52.2 million to:

•


Land	$6,891
Buildings and improvements	39,647
Intangible assets	7,094
Below-market intangibles	(1,289)
Deposit………………………………………………………………………………………..	(150)

Net cash paid	$52,193

New Construction:

During the first quarter of 2016, we committed to invest up to $21.1 million in the development and construction of the Henderson Medical Plaza, an MOB located on the campus of the Henderson Hospital Medical Center which is owned by a UHS subsidiary and opened in late October, 2016. A ground lease has been executed between the limited liability company that owns the MOB and a subsidiary of UHS, the terms of which include a seventy-five year lease term with two ten-year renewal options at the Lessee’s option at an adjusting lease rate. We have invested $4.6 million on the development and construction for this MOB as of September 30, 2016. The MOB is scheduled to be completed and opened during the first quarter of 2017.

Dispositions:

There were no divestitures during the first nine months of 2016.

Nine Months Ended September 30, 2015:

Property Exchange Transaction:

Acquisitions:

Dispositions:

There were no divestitures during the first nine months of 2015.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Summarized Financial Information of Equity Affiliates

9 Months Ended

Sep. 30, 2016

Equity Method Investments And Joint Ventures [Abstract]

Summarized Financial Information of Equity Affiliates

(5) Summarized Financial Information of Equity Affiliates

The following property table represents the five LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of September 30, 2016:


Name of LLC/LP	Ownership			Property Owned by LLC
Suburban Properties		33	%	St. Matthews Medical Plaza II
Brunswick Associates (a.)		74	%	Mid Coast Hospital MOB
Arlington Medical Properties (b.)		85	%	Saint Mary’s Professional Office Building
Grayson Properties (c.)		95	%	Texoma Medical Plaza
FTX MOB Phase II (d.)		95	%	Forney Medical Plaza II

(a.)	This LLC has a third-party term loan, which is non-recourse to us, of $8.7 million outstanding as of September 30, 2016.

(b.)

(c.)

(d.)	We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of September 30, 2016. This LLC has a third-party term loan, which is non-recourse to us, of $5.3 million outstanding as of September 30, 2016.

Below are the condensed combined statements of income (unaudited) for the LLCs accounted for under the equity method at September 30, 2016 and 2015.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
	(amounts in thousands)				(amounts in thousands)
Revenues	$	3,776	$	3,638	$	11,437	$	10,799
Operating expenses		1,329		1,461		4,025		4,194
Depreciation and amortization		646		634		1,910		1,788
Interest, net		636		656		1,928		1,907
Net income	$	1,165	$	887	$	3,574	$	2,910
Our share of net income (a.)	$	1,110	$	561	$	3,396	$	1,826

(a.)

	September 30, 2016			December 31, 2015
	(amounts in thousands)
Net property, including CIP	$	61,317		$	61,668
Other assets		5,343			5,264
Total assets	$	66,660		$	66,932

Liabilities	$	2,832		$	2,538
Mortgage notes payable, non-recourse to us		28,497			28,895
Advances payable to us		21,855			22,489
Equity		13,476			13,010
Total liabilities and equity	$	66,660		$	66,932

Our share of equity in and advances to LLCs reflected as:
Investments in LLCs	$	14,910		$	9,108
Advances to LLCs		21,855			22,489
Investments in and advances to LLCs before
amounts included in accrued expenses and other liabilities		36,765			31,597
Amounts included in accrued expenses and other liabilities		(1,771	)		(1,105	)
Our share of equity in and advances to LLCs, net	$	34,994		$	30,492

	Mortgage Loan Balance (a.)
Name of LLC/LP	9/30/2016		12/31/2015		Maturity Date
FTX MOB Phase II	$	5,333	$	5,427	August, 2017
Grayson Properties		14,496		14,670	September, 2021
Brunswick Associates		8,668		8,798	December, 2024
	$	28,497	$	28,895

(a.)	All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements	9 Months Ended
Recent Accounting Pronouncements	Sep. 30, 2016
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Recent Accounting Pronouncements	(6) Recent Accounting Pronouncements In August, 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which adds or clarifies guidance of the classification of certain cash receipts and payments in the statement of cash flows with the intent to alleviate diversity in practice for classifying various types of cash flows. This ASU is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. We are currently evaluating the impact of this ASU on our statement of cash flows. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASU 2016-02 supersedes the previous leases standard, Leases (Topic 840). The standard is effective on January 1, 2019, with early adoption permitted. We are currently in the process of evaluating the impact the adoption of ASU 2016-02 will have on our financial position or results of operations. In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs, an update to the accounting standard relating to the presentation of debt issuance costs. Under the new guidance, debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability. In the event that there is not an associated debt liability recorded in the consolidated financial statements, the debt issuance costs will continue to be recorded on the consolidated balance sheet as an asset until the debt liability is recorded. The new standard became effective for the Trust on January 1, 2016. The adoption of this guidance did not have a material impact on our consolidated financial position or results of operations as the update only related to changes in financial statement presentation. In February 2015, the FASB issued ASU No. 2015-02, Consolidation – Amendments to the Consolidation Analysis, which amends the current consolidation guidance affecting both the variable interest entity (“VIE”) and voting interest entity (“VOE”) consolidation models. The standard does not add or remove any of the characteristics in determining if an entity is a VIE or VOE, but rather enhances the way the Company assesses some of these characteristics. The new standard became effective for the Trust on January 1, 2016 and did not have a material impact on our consolidated financial position or results of operations as none of its existing consolidation conclusions were changed. In 2014, the FASB issued ASU 2014-09, Revenue From Contracts With Customers (“ASU 2014-09”), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASU 2014-09 states that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment. In 2015, the FASB provided for a one-year deferral of the effective date for ASU 2014-09, which is now effective for us beginning January 1, 2018. We are continuing to evaluate ASU 2014-09 (and related clarifying guidance issued by the FASB); however, we do not expect its adoption to have a significant impact on our consolidated financial statements, as a substantial portion of our revenue consists of rental income from leasing arrangements, which is specifically excluded from ASU 2014-09.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Debt and Financial Instruments

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Debt and Financial Instruments

(7) Debt and Financial Instruments

Debt:

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

	Covenant		September 30, 2016
Tangible net worth	$	125,000	$	172,329
Total leverage	< 60%			47.8	%
Secured leverage	< 30%			17.6	%
Unencumbered leverage	< 60%			48.7	%
Fixed charge coverage	> 1.50x		3.7x

Facility Name	Outstanding Balance (in thousands)(a)		Interest Rate			Maturity Date
Summerlin Hospital Medical Office Building III floating rate mortgage loan (b.)	$	10,462		3.77	%	December, 2016
Peace Health fixed rate mortgage loan (b.)		20,434		5.64	%	April, 2017
Auburn Medical II floating rate mortgage loan (b.)		6,783		3.27	%	April, 2017
Medical Center of Western Connecticut fixed rate mortgage loan (b.)		4,568		6.00	%	June, 2017
Summerlin Hospital Medical Office Building II fixed rate mortgage loan (b.)		11,175		5.50	%	October, 2017
Phoenix Children’s East Valley Care Center fixed rate mortgage loan		6,239		5.88	%	December, 2017
Centennial Hills Medical Office Building floating rate mortgage loan		10,116		3.77	%	January, 2018
Sparks Medical Building/Vista Medical Terrace floating rate mortgage loan		4,260		3.77	%	February, 2018
Rosenberg Children’s Medical Plaza fixed rate mortgage loan		8,190		4.85	%	May, 2018
Vibra Hospital-Corpus Christi fixed rate mortgage loan		2,746		6.50	%	July, 2019
700 Shadow Lane and Goldring MOBs fixed rate mortgage loan		6,294		4.54	%	June, 2022
BRB Medical Office Building fixed rate mortgage loan		6,362		4.27	%	December, 2022
Desert Valley Medical Center fixed rate mortgage loan		5,114		3.62	%	January, 2023
Tuscan Professional Building fixed rate mortgage loan		5,106		5.56	%	June, 2025
Total	$	107,849

(a.)	All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.

(b.)	This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our Credit Agreement.

Financial Instruments:

XML 25 R14.htm IDEA: XBRL DOCUMENT

Segment Reporting	9 Months Ended
Segment Reporting	Sep. 30, 2016
Segment Reporting [Abstract]
Segment Reporting	(8) Segment Reporting Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio. Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables)

9 Months Ended

Sep. 30, 2016

Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities

The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:

Hospital Name	Annual Minimum Rent		End of Lease Term	Renewal Term (years)
McAllen Medical Center	$	5,485,000	December, 2021		10	(a)
Wellington Regional Medical Center	$	3,030,000	December, 2021		10	(b)
Southwest Healthcare System, Inland Valley Campus	$	2,648,000	December, 2021		10	(b)

(a)	UHS has two 5-year renewal options at existing lease rates (through 2031).

(b)	UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).

XML 27 R16.htm IDEA: XBRL DOCUMENT

Acquisitions, Dispositions and New Construction (Tables)

9 Months Ended

Sep. 30, 2016

Business Combinations [Abstract]

Allocation of Purchase Price to Assets Acquired and Liabilities Assumed

The estimated aggregate allocation is as follows:


Land	$6,891
Buildings and improvements	39,647
Intangible assets	7,094
Below-market intangibles	(1,289)
Deposit………………………………………………………………………………………..	(150)

Net cash paid	$52,193

XML 28 R17.htm IDEA: XBRL DOCUMENT

Summarized Financial Information of Equity Affiliates (Tables)

9 Months Ended

Sep. 30, 2016

Equity Method Investments And Joint Ventures [Abstract]

Limited Liability Companies Accounted for Under Equity Method

The following property table represents the five LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of September 30, 2016:


Name of LLC/LP	Ownership			Property Owned by LLC
Suburban Properties		33	%	St. Matthews Medical Plaza II
Brunswick Associates (a.)		74	%	Mid Coast Hospital MOB
Arlington Medical Properties (b.)		85	%	Saint Mary’s Professional Office Building
Grayson Properties (c.)		95	%	Texoma Medical Plaza
FTX MOB Phase II (d.)		95	%	Forney Medical Plaza II

(a.)	This LLC has a third-party term loan, which is non-recourse to us, of $8.7 million outstanding as of September 30, 2016.

(b.)

(c.)

(d.)	We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of September 30, 2016. This LLC has a third-party term loan, which is non-recourse to us, of $5.3 million outstanding as of September 30, 2016.

Condensed Combined Statements of Income (Unaudited) for Limited Liability Companies Accounted for Under Equity Method

Below are the condensed combined statements of income (unaudited) for the LLCs accounted for under the equity method at September 30, 2016 and 2015.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
	(amounts in thousands)				(amounts in thousands)
Revenues	$	3,776	$	3,638	$	11,437	$	10,799
Operating expenses		1,329		1,461		4,025		4,194
Depreciation and amortization		646		634		1,910		1,788
Interest, net		636		656		1,928		1,907
Net income	$	1,165	$	887	$	3,574	$	2,910
Our share of net income (a.)	$	1,110	$	561	$	3,396	$	1,826

(a.)

Condensed Combined Balance Sheets (Unaudited) for LLCs Accounted for Under Equity Method

	September 30, 2016			December 31, 2015
	(amounts in thousands)
Net property, including CIP	$	61,317		$	61,668
Other assets		5,343			5,264
Total assets	$	66,660		$	66,932

Liabilities	$	2,832		$	2,538
Mortgage notes payable, non-recourse to us		28,497			28,895
Advances payable to us		21,855			22,489
Equity		13,476			13,010
Total liabilities and equity	$	66,660		$	66,932

Our share of equity in and advances to LLCs reflected as:
Investments in LLCs	$	14,910		$	9,108
Advances to LLCs		21,855			22,489
Investments in and advances to LLCs before
amounts included in accrued expenses and other liabilities		36,765			31,597
Amounts included in accrued expenses and other liabilities		(1,771	)		(1,105	)
Our share of equity in and advances to LLCs, net	$	34,994		$	30,492

Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's Accounted Under Equity Method

	Mortgage Loan Balance (a.)
Name of LLC/LP	9/30/2016		12/31/2015		Maturity Date
FTX MOB Phase II	$	5,333	$	5,427	August, 2017
Grayson Properties		14,496		14,670	September, 2021
Brunswick Associates		8,668		8,798	December, 2024
	$	28,497	$	28,895

(a.)	All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Debt and Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Summary of Required Compliance Ratios Giving Effect to New Covenants in Credit Agreement

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

	Covenant		September 30, 2016
Tangible net worth	$	125,000	$	172,329
Total leverage	< 60%			47.8	%
Secured leverage	< 30%			17.6	%
Unencumbered leverage	< 60%			48.7	%
Fixed charge coverage	> 1.50x		3.7x

Outstanding Mortgages, Excluding Net Debt Premium

Facility Name	Outstanding Balance (in thousands)(a)		Interest Rate			Maturity Date
Summerlin Hospital Medical Office Building III floating rate mortgage loan (b.)	$	10,462		3.77	%	December, 2016
Peace Health fixed rate mortgage loan (b.)		20,434		5.64	%	April, 2017
Auburn Medical II floating rate mortgage loan (b.)		6,783		3.27	%	April, 2017
Medical Center of Western Connecticut fixed rate mortgage loan (b.)		4,568		6.00	%	June, 2017
Summerlin Hospital Medical Office Building II fixed rate mortgage loan (b.)		11,175		5.50	%	October, 2017
Phoenix Children’s East Valley Care Center fixed rate mortgage loan		6,239		5.88	%	December, 2017
Centennial Hills Medical Office Building floating rate mortgage loan		10,116		3.77	%	January, 2018
Sparks Medical Building/Vista Medical Terrace floating rate mortgage loan		4,260		3.77	%	February, 2018
Rosenberg Children’s Medical Plaza fixed rate mortgage loan		8,190		4.85	%	May, 2018
Vibra Hospital-Corpus Christi fixed rate mortgage loan		2,746		6.50	%	July, 2019
700 Shadow Lane and Goldring MOBs fixed rate mortgage loan		6,294		4.54	%	June, 2022
BRB Medical Office Building fixed rate mortgage loan		6,362		4.27	%	December, 2022
Desert Valley Medical Center fixed rate mortgage loan		5,114		3.62	%	January, 2023
Tuscan Professional Building fixed rate mortgage loan		5,106		5.56	%	June, 2025
Total	$	107,849

(a.)	All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.

(b.)	This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our Credit Agreement.

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

General - Additional Information (Detail)	Sep. 30, 2016 Property
5 Unconsolidated Limited Liability Companies \| Minimum
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Non-controlling equity interest, ownership percentage	33.00%
5 Unconsolidated Limited Liability Companies \| Maximum
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Non-controlling equity interest, ownership percentage	95.00%
Medical office buildings \| Limited Liability Companies
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of real estate investments	5

XML 31 R20.htm IDEA: XBRL DOCUMENT

Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail)	1 Months Ended	3 Months Ended			9 Months Ended
	Jun. 30, 2016 Subsidiary Time	Sep. 30, 2016 USD ($) Time	Mar. 31, 2016 USD ($) Time	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) Property Time	Sep. 30, 2015 USD ($)	Dec. 31, 2015
Related Party Transaction [Line Items]
Advisory fee		$ 832,000		$ 708,000	$ 2,380,000	$ 2,067,000
Minimum \| 5 Unconsolidated Limited Liability Companies
Related Party Transaction [Line Items]
Non-controlling equity interest, ownership percentage		33.00%			33.00%
Maximum \| 5 Unconsolidated Limited Liability Companies
Related Party Transaction [Line Items]
Non-controlling equity interest, ownership percentage		95.00%			95.00%
Universal Health Services, Inc
Related Party Transaction [Line Items]
Number of term renewal options \| Time		6			6
Additional renewal terms					5 years
Number of medical office buildings and free standing emergency departments \| Property					17
Number of medical office buildings under construction \| Property					1
Option to renew lease, notice period prior to termination date of current term					90 days
Period to purchase respective leased facilities at same price after lease terms					180 days
Renewal period of respective leased facilities at same price after lease terms					180 days
Number of wholly-owned subsidiaries \| Subsidiary	3
Extended lease terms at existing lease rates					2021-12
Number of renewal options at existing lease rates \| Time	3
Percentage ownership of outstanding shares		5.80%			5.80%		5.90%
Universal Health Services, Inc \| Henderson Medical Plaza
Related Party Transaction [Line Items]
Number of term renewal options \| Time			2
Additional renewal terms			10 years
Maximum amount of investment for development and construction			$ 21,100,000
Ground lease agreement period			75 years
Amount invested in MOB under construction		$ 4,600,000			$ 4,600,000
Universal Health Services, Inc \| Customer Concentration Risk \| Revenues
Related Party Transaction [Line Items]
Percentage of revenues generated from leases		23.00%		25.00%	24.00%	25.00%
Universal Health Services, Inc \| Customer Concentration Risk \| Combined consolidated and unconsolidated revenue
Related Party Transaction [Line Items]
Percentage of revenues generated from leases		19.00%		20.00%	20.00%	20.00%
Universal Health Services, Inc \| Minimum
Related Party Transaction [Line Items]
Initial lease terms					13 years
Universal Health Services, Inc \| Maximum
Related Party Transaction [Line Items]
Initial lease terms					15 years
Universal Health Services of Delaware Inc
Related Party Transaction [Line Items]
Annual incentive fee to Advisor as percentage of cash available for distribution		20.00%			20.00%
Incentive fees					$ 0	$ 0
Advisory fee		$ 832,000		$ 708,000	2,400,000	2,100,000
Average invested real estate assets		$ 475,000,000		$ 405,000,000	$ 453,000,000	$ 394,000,000
Universal Health Services of Delaware Inc \| Minimum
Related Party Transaction [Line Items]
Percentage of equity to be exceeded for incentive distribution		15.00%			15.00%

XML 32 R21.htm IDEA: XBRL DOCUMENT

Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail)

9 Months Ended

Sep. 30, 2016

USD ($)

McAllen Medical Center

Operating Leased Assets [Line Items]

Annual Minimum Rent

$ 5,485,000

End of Lease Term

2021-12

Renewal Term (years)

10 years

^[1]

Wellington Regional Medical Center

Operating Leased Assets [Line Items]

Annual Minimum Rent

$ 3,030,000

End of Lease Term

2021-12

Renewal Term (years)

10 years

^[2]

Southwest Healthcare System, Inland Valley Campus

Operating Leased Assets [Line Items]

Annual Minimum Rent

$ 2,648,000

End of Lease Term

2021-12

Renewal Term (years)

10 years

^[2]

[1]	UHS has two 5-year renewal options at existing lease rates (through 2031).
[2]	UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).

XML 33 R22.htm IDEA: XBRL DOCUMENT

Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) - Universal Health Services, Inc	1 Months Ended	9 Months Ended
	Jun. 30, 2016 Time	Sep. 30, 2016 Time RenewalOption
Operating Leased Assets [Line Items]
Number of renewal options at existing lease rates	3
McAllen Medical Center
Operating Leased Assets [Line Items]
Number of renewal options at existing lease rates		2
Renewal options term at existing lease rates		5 years
Renewal options at existing lease rates expiration year		2031
Wellington Regional Medical Center And Southwest Healthcare System
Operating Leased Assets [Line Items]
Number of renewal options at fair market value lease rates \| RenewalOption		2
Renewal options term at fair market value lease rates		5 years
Wellington Regional Medical Center And Southwest Healthcare System \| Minimum
Operating Leased Assets [Line Items]
Renewal options at fair market value lease rates expiration year		2022
Wellington Regional Medical Center And Southwest Healthcare System \| Maximum
Operating Leased Assets [Line Items]
Renewal options at fair market value lease rates expiration year		2031

XML 34 R23.htm IDEA: XBRL DOCUMENT

Dividends and Equity Issuance Program - Additional Information (Detail) - USD ($)	3 Months Ended			9 Months Ended		36 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016
Dividends and Equity Issuance [Line Items]
Dividends declared and paid	$ 8,800,000		$ 8,500,000	$ 26,231,000	$ 25,494,000
Declared and paid dividends, per share	$ 0.65		$ 0.64	$ 1.945	$ 1.915
Securities, aggregate sales price		$ 23,300,000
At-The-Market (ATM) Equity Issuance Program
Dividends and Equity Issuance [Line Items]
Share issued		249,016		249,016		829,916
Average sale price per share		$ 55.30		$ 55.30		$ 48.77
Net cash proceeds from stock issued				$ 13,200,000		$ 38,800,000
Payment of stock issuance cost				558,000		1,700,000
Payments for stock issuance				344,000		1,000,000
At-The-Market (ATM) Equity Issuance Program \| Other Expense
Dividends and Equity Issuance [Line Items]
Payments for stock issuance				$ 214,000		$ 680,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

Acquisitions, Dispositions and New Construction - Additional Information (Detail)	1 Months Ended		2 Months Ended	3 Months Ended				9 Months Ended		12 Months Ended
	May 31, 2015 USD ($) ft² Property	Feb. 28, 2015 USD ($) ft² Building	Feb. 28, 2015 USD ($) ft² Property	Sep. 30, 2016 USD ($) ft² Time	Jun. 30, 2016 USD ($) ft²	Mar. 31, 2016 USD ($) ft² Time	Sep. 30, 2015 USD ($) $ / shares	Sep. 30, 2016 USD ($) ft² Time	Sep. 30, 2015 USD ($) $ / shares	Dec. 31, 2015 USD ($)
Business Acquisitions And Dispositions [Line Items]
Total cash paid								$ 52,200,000
Deposits on real estate assets								420,000
Business combination recorded aggregate net revenue				$ 723,000				1,100,000
Business combination aggregate net losses generated by properties including cost of borrowings and advisory fee expenses				47,000				134,000
Business acquisition, pro forma net revenues				$ 17,200,000			$ 16,400,000	51,700,000	$ 50,100,000
Business Acquisition, pro forma net income							$ 3,400,000		$ 18,700,000
Business Acquisition, pro forma diluted per share \| $ / shares							$ 0.25		$ 1.40
Cash received for property exchange transaction								$ 0	$ 2,000,000
Gain on property exchange									8,742,000
Universal Health Services, Inc
Business Acquisitions And Dispositions [Line Items]
Number of term renewal options \| Time				6				6
Additional renewal terms								5 years
Henderson Medical Plaza \| Universal Health Services, Inc
Business Acquisitions And Dispositions [Line Items]
Maximum amount of investment for development and construction						$ 21,100,000
Amount invested in MOB under construction				$ 4,600,000				$ 4,600,000
Ground lease agreement period						75 years
Number of term renewal options \| Time						2
Additional renewal terms						10 years
Sheffield Medical Building
Business Acquisitions And Dispositions [Line Items]
Net rentable area \| ft²	36,700
Cash received for property exchange transaction	$ 2,000,000
Area of disposed building \| ft²	73,446
Number of assets acquired \| Property	2
Percentage of rentable area covered by the agreement	100.00%
Lease agreement period	15 years
Percentage of annual rent increase	3.00%
Gain on property exchange									8,700,000
Minimum
Business Acquisitions And Dispositions [Line Items]
Acquired intangible assets include in-place leases amortization period								6 years
Maximum
Business Acquisitions And Dispositions [Line Items]
Acquired intangible assets include in-place leases amortization period								12 years
Frederick Memorial Hospital Crestwood
Business Acquisitions And Dispositions [Line Items]
Total purchase price				$ 24,300,000
Net rentable area \| ft²				62,300				62,300
Frederick Memorial Hospital Crestwood \| Lease Agreements
Business Acquisitions And Dispositions [Line Items]
Renewal Term (years)				12 years
Chandler Corporate Center III
Business Acquisitions And Dispositions [Line Items]
Total purchase price					$ 18,000,000
Net rentable area \| ft²					82,000
Occupied percentage of property					92.00%
Lease rent escalation period					12 years
Lessor Leasing Arrangements, Operating Leases, Renewal Term					10 years
Chandler Corporate Center III \| Lease Agreements
Business Acquisitions And Dispositions [Line Items]
Renewal Term (years)					11 years 3 months 18 days
Madison Professional Office Building
Business Acquisitions And Dispositions [Line Items]
Total purchase price						$ 10,100,000
Net rentable area \| ft²						30,100
Deposits on real estate assets										$ 150,000
Madison Professional Office Building \| Lease Agreements
Business Acquisitions And Dispositions [Line Items]
Renewal Term (years)						6 years 2 months 12 days
Haas Medical Office Park
Business Acquisitions And Dispositions [Line Items]
Total purchase price		$ 4,100,000
Net rentable area \| ft²		16,000	16,000
Number of Buildings purchased \| Building		2
Wholly Owned Subsidiaries Of U H S Real Property Of Two Newly Constructed And Recently Opened F E Ds Located In Weslaco And Mission Texas
Business Acquisitions And Dispositions [Line Items]
Total purchase price			$ 12,800,000
Additional renewal terms			5 years
Cash received for property exchange transaction									$ 0
Number of real properties purchased \| Property			2
Lease agreement period			10 years
Wholly Owned Subsidiaries Of U H S Real Property Of Two Newly Constructed And Recently Opened F E Ds Located In Weslaco And Mission Texas \| Recently Opened Free Standing Emergency Departments \| Weslaco
Business Acquisitions And Dispositions [Line Items]
Area of acquired building \| ft²		13,600	13,600
Wholly Owned Subsidiaries Of U H S Real Property Of Two Newly Constructed And Recently Opened F E Ds Located In Weslaco And Mission Texas \| Recently Opened Free Standing Emergency Departments \| Mission
Business Acquisitions And Dispositions [Line Items]
Area of acquired building \| ft²		13,600	13,600

XML 36 R25.htm IDEA: XBRL DOCUMENT

Allocation of Purchase Price to Assets Acquired and Liabilities Assumed (Detail) $ in Thousands	Sep. 30, 2016 USD ($)
Business Combinations [Abstract]
Land	$ 6,891
Buildings and improvements	39,647
Intangible assets	7,094
Below-market intangibles	(1,289)
Deposit	(150)
Net cash paid	$ 52,193

XML 37 R26.htm IDEA: XBRL DOCUMENT

Summarized Financial Information of Equity Affiliates - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2016 Property
Limited Liability Companies \| Medical office buildings
Schedule Of Equity Method Investments [Line Items]
Number of real estate investments	5
Minimum
Schedule Of Equity Method Investments [Line Items]
Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member	60 days
Maximum
Schedule Of Equity Method Investments [Line Items]
Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member	90 days
5 Unconsolidated Limited Liability Companies / Limited Partner \| Minimum
Schedule Of Equity Method Investments [Line Items]
Non-controlling equity interest, ownership percentage	33.00%
5 Unconsolidated Limited Liability Companies / Limited Partner \| Maximum
Schedule Of Equity Method Investments [Line Items]
Non-controlling equity interest, ownership percentage	95.00%
Arlington Medical Properties
Schedule Of Equity Method Investments [Line Items]
Non-controlling equity interest, ownership percentage	85.00%
Percentage of minority ownership purchased from third-party members	10.00%

XML 38 R27.htm IDEA: XBRL DOCUMENT

Limited Liability Companies Accounted for Under Equity Method (Detail)

9 Months Ended

Sep. 30, 2016

Arlington Medical Properties

Schedule Of Equity Method Investments [Line Items]

Ownership

85.00%

Equity Method Investments | Suburban Properties

Schedule Of Equity Method Investments [Line Items]

Ownership

33.00%

Property Owned by LLC

St. Matthews Medical Plaza II

Equity Method Investments | Brunswick Associates

Schedule Of Equity Method Investments [Line Items]

Ownership

74.00%

^[1]

Property Owned by LLC

Mid Coast Hospital MOB

^[1]

Equity Method Investments | Arlington Medical Properties

Schedule Of Equity Method Investments [Line Items]

Ownership

85.00%

^[2]

Property Owned by LLC

Saint Mary’s Professional Office Building

^[2]

Equity Method Investments | Grayson Properties

Schedule Of Equity Method Investments [Line Items]

Ownership

95.00%

^[3]

Property Owned by LLC

Texoma Medical Plaza

^[3]

Equity Method Investments | FTX MOB Phase II limited partnership

Schedule Of Equity Method Investments [Line Items]

Ownership

95.00%

^[4]

Property Owned by LLC

Forney Medical Plaza II

^[4]

[1]	This LLC has a third-party term loan, which is non-recourse to us, of $8.7 million outstanding as of September 30, 2016.
[2]	We have funded $5.2 million in equity as of September 30, 2016 and are committed to invest an additional $623,000. During the fourth quarter of 2015, we advanced this LLC a member loan, the funds of which were utilized to repay its $22.8 million outstanding third-party mortgage loan on its scheduled maturity date. The terms of the member loan are similar to those in place pursuant to the third-party mortgage loan that was repaid. Additionally, pursuant to the terms and conditions of an agreement executed in February, 2016, we purchased an additional 10% of the ownership interest in this LLC from the existing third-party member for approximately $4.8 million in cash, thereby increasing our ownership interest to 85%.
[3]	We have funded $2.8 million in equity as of September 30, 2016, and are committed to fund an additional $100,000. This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LLC has a third-party term loan, which is non-recourse to us, of $14.5 million outstanding as of September 30, 2016.
[4]	We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of September 30, 2016. This LLC has a third-party term loan, which is non-recourse to us, of $5.3 million outstanding as of September 30, 2016.

XML 39 R28.htm IDEA: XBRL DOCUMENT

Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2015	Sep. 30, 2016
Brunswick Associates
Schedule Of Equity Method Investments [Line Items]
Third-party term loan		$ 8,700,000
Arlington Medical Properties
Schedule Of Equity Method Investments [Line Items]
Committed investment in equity and debt financing, funded		5,200,000
Commitment to investment		$ 623,000
Proceeds from Lines of Credit	$ 22,800,000
Percentage of minority ownership purchased from third-party members		10.00%
Business acquisition additional consideration		$ 4,800,000
Cash payment made purchased addition of ownership interest		85.00%
Grayson Properties
Schedule Of Equity Method Investments [Line Items]
Third-party term loan		$ 14,500,000
Committed investment in equity and debt financing, funded		2,800,000
Commitment to investment		100,000
FTX MOB Phase II limited partnership
Schedule Of Equity Method Investments [Line Items]
Third-party term loan		5,300,000
Committed investment in equity and debt financing, funded		2,100,000
Commitment to investment		$ 2,500,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Equity Method Investments And Joint Ventures [Abstract]

Revenues

$ 3,776

$ 3,638

$ 11,437

$ 10,799

Operating expenses

1,329

1,461

4,025

4,194

Depreciation and amortization

646

634

1,910

1,788

Interest, net

636

656

1,928

1,907

Net income

1,165

887

3,574

2,910

Our share of net income

^[1]

$ 1,110

$ 561

$ 3,396

$ 1,826

[1]

XML 41 R30.htm IDEA: XBRL DOCUMENT

Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Schedule Of Equity Method Investments [Line Items]
Advances payable to us	$ 21,855,000		$ 21,855,000		$ 22,489,000
Arlington Medical Properties
Schedule Of Equity Method Investments [Line Items]
Interest income earned on various advances made to LLCs	291,000	$ 0	880,000	$ 0
Advances payable to us	$ 21,800,000		$ 21,800,000
Percentage of minority ownership purchased from third-party members	10.00%		10.00%
Cash payment made purchased addition of ownership interest			85.00%		75.00%

XML 42 R31.htm IDEA: XBRL DOCUMENT

Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Equity Method Investments And Joint Ventures [Abstract]
Net property, including CIP	$ 61,317	$ 61,668
Other assets	5,343	5,264
Total assets	66,660	66,932
Liabilities	2,832	2,538
Mortgage notes payable, non-recourse to us	28,497	28,895
Advances payable to us	21,855	22,489
Equity	13,476	13,010
Total liabilities and equity	66,660	66,932
Our share of equity in and advances to LLCs reflected as:
Investments in LLCs	14,910	9,108
Advances to LLCs	21,855	22,489
Investments in and advances to LLCs before amounts included in accrued expenses and other liabilities	36,765	31,597
Amounts included in accrued expenses and other liabilities	(1,771)	(1,105)
Our share of equity in and advances to LLCs, net	$ 34,994	$ 30,492

XML 43 R32.htm IDEA: XBRL DOCUMENT

Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) - USD ($)
$ in Thousands

9 Months Ended

Sep. 30, 2016

Dec. 31, 2015

Schedule Of Equity Method Investments [Line Items]

Mortgage Loan Balance

$ 28,497

$ 28,895

Equity Method Investments

Schedule Of Equity Method Investments [Line Items]

Mortgage Loan Balance

^[1]

28,497

28,895

Equity Method Investments | FTX MOB Phase II

Schedule Of Equity Method Investments [Line Items]

Mortgage Loan Balance

^[1]

$ 5,333

5,427

Maturity Date

2017-08

Equity Method Investments | Grayson Properties

Schedule Of Equity Method Investments [Line Items]

Mortgage Loan Balance

^[1]

$ 14,496

14,670

Maturity Date

2021-09

Equity Method Investments | Brunswick Associates

Schedule Of Equity Method Investments [Line Items]

Mortgage Loan Balance

^[1]

$ 8,668

$ 8,798

Maturity Date

2024-12

[1]	All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.

XML 44 R33.htm IDEA: XBRL DOCUMENT

Debt and Financial Instruments - Additional Information (Detail)

3 Months Ended

9 Months Ended

Sep. 30, 2016

USD ($)

MortgageLoan

Derivative

Mar. 27, 2015

USD ($)

Option

Sep. 30, 2016

USD ($)

MortgageLoan

Derivative

Jun. 30, 2016

USD ($)

Derivative

Mar. 31, 2014

USD ($)

Derivative

Sep. 30, 2013

USD ($)

Derivative

Sep. 30, 2016

USD ($)

MortgageLoan

Derivative

May 24, 2016

USD ($)

Dec. 31, 2015

USD ($)

MortgageLoan

Debt Instrument [Line Items]

Outstanding borrowings under credit agreement

$ 192,250,000

$ 142,150,000

Outstanding borrowings under letter of credit

2,700,000

Available borrowing capacity

$ 55,000,000

Number of non-recourse mortgages | MortgageLoan

Balance of Non Recourse Mortgages

$ 107,849,000

^[1]

$ 107,849,000

^[1]

$ 107,849,000

^[1]

$ 110,300,000

Mortgage and other notes payable, non-recourse to us, debt premium

132,000,000

298,000

Financing fees net

321,000,000

398,000

Mortgage loan fair value

$ 110,000,000

$ 112,000,000

Interest Rate Cap

Debt Instrument [Line Items]

Number of interest rate cap agreements | Derivative

Notional amount

$ 30,000,000

$ 20,000,000

$ 10,000,000

$ 30,000,000

Premium paid

$ 55,000

$ 115,000

$ 134,500

$ 136,000

Expiration date of interest rate cap

Mar. 31, 2019

Jan. 31, 2017

LIBOR | Interest Rate Cap

Debt Instrument [Line Items]

Derivative instruments, LIBOR rate

1.50%

Credit Agreement

Debt Instrument [Line Items]

Outstanding borrowing

$ 185,000,000

$ 250,000,000

Unsecured revolving amended credit agreement terminated date

2019-03

Number of additional one year extension options | Option

Proceeds from Lines of Credit

$ 50,000,000

Credit facility, Interest Rate Terms

One, two, three, or six month LIBOR plus an applicable margin ranging from 1.50% to 2.00% or at the Base Rate plus an applicable margin ranging from 0.50% to 1.00%.

Base rate description

The greatest of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%.

Fee payable on unused portion of commitment

0.25%

Credit Agreement | LIBOR

Debt Instrument [Line Items]

Margin points added to the reference rate

1.625%

Credit Agreement | Base Rate

Debt Instrument [Line Items]

Margin points added to the reference rate

0.625%

Credit Agreement | Swingline/Short-Term Loans

Debt Instrument [Line Items]

Outstanding borrowing

20,000,000

Credit Agreement | Letters of Credit

Debt Instrument [Line Items]

Outstanding borrowing

$ 40,000,000

Minimum | Credit Agreement

Debt Instrument [Line Items]

Fee payable on unused portion of commitment

0.20%

Minimum | Credit Agreement | LIBOR

Debt Instrument [Line Items]

Margin points added to the reference rate

1.50%

Margin points added to the base rate

1.00%

Minimum | Credit Agreement | Base Rate

Debt Instrument [Line Items]

Margin points added to the reference rate

0.50%

Minimum | Credit Agreement | Federal Funds Effective Rate

Debt Instrument [Line Items]

Margin points added to the base rate

0.50%

Maximum | Credit Agreement

Debt Instrument [Line Items]

Fee payable on unused portion of commitment

0.40%

Maximum | Credit Agreement | LIBOR

Debt Instrument [Line Items]

Margin points added to the reference rate

2.00%

Maximum | Credit Agreement | Base Rate

Debt Instrument [Line Items]

Margin points added to the reference rate

1.00%

[1]	All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.

XML 45 R34.htm IDEA: XBRL DOCUMENT

Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Debt Instrument [Line Items]
Covenant, Tangible net worth	$ 125,000
Tangible net worth	$ 172,329
Total leverage	47.80%
Secured leverage	17.60%
Unencumbered leverage	48.70%
Fixed charge coverage	3.70%
Maximum
Debt Instrument [Line Items]
Covenant, Total leverage	60.00%
Covenant, Secured leverage	30.00%
Covenant, Unencumbered leverage	60.00%
Minimum
Debt Instrument [Line Items]
Covenant, Fixed charge coverage	1.50%

XML 46 R35.htm IDEA: XBRL DOCUMENT

Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) - USD ($)
$ in Thousands

9 Months Ended

Sep. 30, 2016

Dec. 31, 2015

Debt Instrument [Line Items]

Outstanding Balance

$ 107,849

^[1]

$ 110,300

Summerlin Hospital Medical Office Building III floating rate mortgage loan

Debt Instrument [Line Items]

Outstanding Balance

^[1],[2]

$ 10,462

Debt Instrument Interest Rate Stated Percentage

^[2]

3.77%

Maturity Date

^[2]

2016-12

Peace Health fixed rate mortgage loan

Debt Instrument [Line Items]

Outstanding Balance

^[1],[2]

$ 20,434

Debt Instrument Interest Rate Stated Percentage

^[2]

5.64%

Maturity Date

^[2]

2017-04

Auburn Medical II floating rate mortgage loan

Debt Instrument [Line Items]

Outstanding Balance

^[1],[2]

$ 6,783

Debt Instrument Interest Rate Stated Percentage

^[2]

3.27%

Maturity Date

^[2]

2017-04

Medical Center of Western Connecticut fixed rate mortgage loan

Debt Instrument [Line Items]

Outstanding Balance

^[1],[2]

$ 4,568

Debt Instrument Interest Rate Stated Percentage

^[2]

6.00%

Maturity Date

^[2]

2017-06

Summerlin Hospital Medical Office Building II fixed rate mortgage loan

Debt Instrument [Line Items]

Outstanding Balance

^[1]

$ 11,175

Debt Instrument Interest Rate Stated Percentage

5.50%

Maturity Date

2017-10

Phoenix Children's East Valley Care Center Fixed Rate Mortgage Loan

Debt Instrument [Line Items]

Outstanding Balance

^[1]

$ 6,239

Debt Instrument Interest Rate Stated Percentage

5.88%

Maturity Date

2017-12

Centennial Hills Medical Office Building floating rate mortgage loan

Debt Instrument [Line Items]

Outstanding Balance

^[1]

$ 10,116

Debt Instrument Interest Rate Stated Percentage

3.77%

Maturity Date

2018-01

Sparks Medical Building/Vista Medical Terrace Floating Rate Mortgage Loan

Debt Instrument [Line Items]

Outstanding Balance

^[1]

$ 4,260

Debt Instrument Interest Rate Stated Percentage

3.77%

Maturity Date

2018-02

Rosenberg Children's Medical Plaza Fixed Rate Mortgage Loan

Debt Instrument [Line Items]

Outstanding Balance

^[1]

$ 8,190

Debt Instrument Interest Rate Stated Percentage

4.85%

Maturity Date

2018-05

Vibra Hospital-Corpus Christi fixed rate mortgage loan

Debt Instrument [Line Items]

Outstanding Balance

^[1]

$ 2,746

Debt Instrument Interest Rate Stated Percentage

6.50%

Maturity Date

2019-07

700 Shadow Lane and Goldring MOBs fixed rate mortgage loan

Debt Instrument [Line Items]

Outstanding Balance

^[1]

$ 6,294

Debt Instrument Interest Rate Stated Percentage

4.54%

Maturity Date

2022-06

BRB Medical Office Building fixed rate mortgage loan

Debt Instrument [Line Items]

Outstanding Balance

^[1]

$ 6,362

Debt Instrument Interest Rate Stated Percentage

4.27%

Maturity Date

2022-12

Desert Valley Medical Center Floating Rate Mortgage Loan

Debt Instrument [Line Items]

Outstanding Balance

^[1]

$ 5,114

Debt Instrument Interest Rate Stated Percentage

3.62%

Maturity Date

2023-01

Tuscan Professional Building fixed rate mortgage loan

Debt Instrument [Line Items]

Outstanding Balance

^[1]

$ 5,106

Debt Instrument Interest Rate Stated Percentage

5.56%

Maturity Date

2025-06

[1]	All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.
[2]	This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our Credit Agreement.

XML 47 R36.htm IDEA: XBRL DOCUMENT

Segment Reporting - Additional Information (Detail)	9 Months Ended
Segment Reporting - Additional Information (Detail)	Sep. 30, 2016 Segment
Segment Reporting [Abstract]
Number of reportable segments	1

EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 49 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 160 241 1 true 60 0 false 14 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.uhrit.com/20160930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Statements of Income Sheet http://www.uhrit.com/20160930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome Condensed Consolidated Statements of Income Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.uhrit.com/20160930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.uhrit.com/20160930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.uhrit.com/20160930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statement of Cash Flows Sheet http://www.uhrit.com/20160930/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows Condensed Consolidated Statement of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - General Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureGeneral General Notes 7 false false R8.htm 100070 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Notes 8 false false R9.htm 100080 - Disclosure - Dividends and Equity Issuance Program Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgram Dividends and Equity Issuance Program Notes 9 false false R10.htm 100090 - Disclosure - Acquisitions, Dispositions and New Construction Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureAcquisitionsDispositionsAndNewConstruction Acquisitions, Dispositions and New Construction Notes 10 false false R11.htm 100100 - Disclosure - Summarized Financial Information of Equity Affiliates Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates Summarized Financial Information of Equity Affiliates Notes 11 false false R12.htm 100110 - Disclosure - Recent Accounting Pronouncements Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureRecentAccountingPronouncements Recent Accounting Pronouncements Notes 12 false false R13.htm 100120 - Disclosure - Debt and Financial Instruments Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureDebtAndFinancialInstruments Debt and Financial Instruments Notes 13 false false R14.htm 100130 - Disclosure - Segment Reporting Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureSegmentReporting Segment Reporting Notes 14 false false R15.htm 100140 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) Tables http://www.uhrit.com/20160930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions 15 false false R16.htm 100150 - Disclosure - Acquisitions, Dispositions and New Construction (Tables) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureAcquisitionsDispositionsAndNewConstructionTables Acquisitions, Dispositions and New Construction (Tables) Tables http://www.uhrit.com/20160930/taxonomy/role/DisclosureAcquisitionsDispositionsAndNewConstruction 16 false false R17.htm 100160 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables Summarized Financial Information of Equity Affiliates (Tables) Tables http://www.uhrit.com/20160930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates 17 false false R18.htm 100170 - Disclosure - Debt and Financial Instruments (Tables) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsTables Debt and Financial Instruments (Tables) Tables http://www.uhrit.com/20160930/taxonomy/role/DisclosureDebtAndFinancialInstruments 18 false false R19.htm 100180 - Disclosure - General - Additional Information (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail General - Additional Information (Detail) Details 19 false false R20.htm 100190 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) Details http://www.uhrit.com/20160930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables 20 false false R21.htm 100200 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) Details 21 false false R22.htm 100210 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) Details 22 false false R23.htm 100220 - Disclosure - Dividends and Equity Issuance Program - Additional Information (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail Dividends and Equity Issuance Program - Additional Information (Detail) Details 23 false false R24.htm 100230 - Disclosure - Acquisitions, Dispositions and New Construction - Additional Information (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureAcquisitionsDispositionsAndNewConstructionAdditionalInformationDetail Acquisitions, Dispositions and New Construction - Additional Information (Detail) Details 24 false false R25.htm 100240 - Disclosure - Allocation of Purchase Price to Assets Acquired and Liabilities Assumed (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureAllocationOfPurchasePriceToAssetsAcquiredAndLiabilitiesAssumedDetail Allocation of Purchase Price to Assets Acquired and Liabilities Assumed (Detail) Details 25 false false R26.htm 100250 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail Summarized Financial Information of Equity Affiliates - Additional Information (Detail) Details 26 false false R27.htm 100260 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail Limited Liability Companies Accounted for Under Equity Method (Detail) Details 27 false false R28.htm 100270 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) Details 28 false false R29.htm 100280 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLimitedLiabilitiesAccountedForUnderEquityMethodDetail Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) Details 29 false false R30.htm 100290 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLimitedLiabilitiesAccountedForUnderEquityMethodParentheticalDetail Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) Details 30 false false R31.htm 100300 - Disclosure - Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsOfLimitedLiabilitiesAccountedForUnderEquityMethodDetail Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) Details 31 false false R32.htm 100310 - Disclosure - Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) Notes http://www.uhrit.com/20160930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcsAccountedUnderEquityMethodDetail Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) Details 32 false false R33.htm 100320 - Disclosure - Debt and Financial Instruments - Additional Information (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail Debt and Financial Instruments - Additional Information (Detail) Details 33 false false R34.htm 100330 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) Details 34 false false R35.htm 100340 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) Details 35 false false R36.htm 100350 - Disclosure - Segment Reporting - Additional Information (Detail) Sheet http://www.uhrit.com/20160930/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail Segment Reporting - Additional Information (Detail) Details 36 false false All Reports Book All Reports uht-20160930.xml uht-20160930.xsd uht-20160930_cal.xml uht-20160930_def.xml uht-20160930_lab.xml uht-20160930_pre.xml true true ZIP 54 0001564590-16-028351-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-16-028351-xbrl.zip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end